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Background: Arterial stiffness and endothelial dysfunction are implicated in the
pathogenesis of atherosclerosis. Both are present in patients with
hypercholesterolaemia and diabetes mellitus, and are markers of future
cardiovascular events in patients with coronary artery disease (CAD), hypertension
and end-stage renal failure. The structural components, elastin and collagen, which
influence skin elasticity are also responsible for the elasticity of arteries.
Aims: To investigate: 1. The association between skin elasticity and arterial
elasticity in healthy subjects. 2. The determinants of arterial stiffness in patients with
CAD, particularly renal function. 3. The determinants of endothelial dysfunction in
patients with CAD. 4. The association between arterial stiffness and endothelial
dysfunction in patients with CAD. 5. The survival of subjects from cardiovascular
morbidity and mortality as determined by the severity of CAD, renal function,
arterial stiffness and endothelial function.
Methods: Skin elasticity was measured in the arm, leg and back using a suction
device which measures the vertical deformation of skin. Arterial stiffness was
assessed using pressure pulse wave velocity (PWV), pulse wave analysis (PWA) and
digital volume pulse (DVP) analysis. Endothelial function was determined non-
invasively using PWA with the administration of glyceryl trinitrate (endothelium-
independent vasodilator) and salbutamol (endothelium-dependent vasodilator). The
study in CAD was a cohort study with longitudinal follow up for a median of 18
months. Adverse clinical events were determined through the Information and
Statistics Division of the NHS and the General Register Office in Scotland. Renal
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function was assessed using serum creatinine concentration ([creat]sr) and estimated
glomerular filtration rate (eGFR) by using creatinine clearance calculated using the
Cockcroft & Gault equation. Subjects with a history of renal disease were excluded.
The primary-endpoint was a composite of hospitalisation and mortality due to
cardiovascular causes.
Results: 1. Arterial elasticity and skin elasticity were only weakly associated. 2.
Arterial stiffness was determined by age, heart rate, central systolic blood pressure
and [creat]sr (R2=0.38, P < 0.001). Arterial stiffness was negatively associated with
eGFR (R2=0.30, P < 0.001), even within the normal range. 3. Endothelium-
independent changes in the augmentation indices (AIs) were determined by age,
body mass index and mean blood pressure (R2=0.09, P < 0.001). Endothelium-
dependent changes in AIs were weakly explained by mean blood pressure (R2=0.02,
P < 0.001) but not associated with hypercholesterolaemia, as previously reported, or
renal function. However, the presence or severity of CAD did not explain the
variance in arterial stiffness or endothelial function measures. 4. Endothelium-
independent and dependent changes in AIs were positively correlated. In addition,
endothelium-independent changes in AIs were lower in subjects with stiffer arteries
(r = 0.20, P < 0.01). 5. Subjects with a high number of diseased coronary vessels (P <
0.001), a low eGFR (P < 0.01), or a PWV above the median (P < 0.05) had a higher
risk of developing adverse clinical events. Endothelial function, however, did not
appear to predict a poor outcome.
Conclusion: In healthy subjects, skin elasticity is an unreliable marker of arterial
elasticity. An important finding in the CAD study was that renal function was a
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determinant of arterial stiffness in patients without a history of renal disease. In this
treated group of subjects, traditional cardiovascular risk factors did not determine
arterial stiffness or endothelial dysfunction and there was no association between
arterial stiffness and endothelial dysfunction. Moreover, endothelial function
measured using PWA, with the administration of GTN and salbutamol, is not a
useful test in patients with CAD on drug treatment. However, the presence and
severity ofCAD, renal function, as well as the stiffness of arteries, are predictive of a
shorter time to fatal and non-fatal cardiovascular outcomes.
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MRI Magnetic resonance imaging
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Coronary heart disease (CHD) is the leading cause ofmorbidity and mortality among
adults in Europe and North America. Cardiovascular disease (CVD) accounts for
about 233,000 deaths a year (38% of all deaths) in the United Kingdom [Petersen et
al. 2005]. Coronary artery disease (CAD) and stroke are the main types of CVD and
account for about half and one-quarter of all CVD deaths respectively. CHD is a
common cause of premature death (age less than 75 years) accounting for 22% of
deaths in men, and 12% in women. About 270,000 people suffer a heart attack each
year, with under a third of them dying before they reach hospital. Although the
mortality rate from CHD has declined over the last few years, the rate of morbidity
due to heart disease has increased. It is estimated that that about 1.2 million people
currently living in the U.K. have had a heart attack and around 2 million suffer from
angina. CVD is a common cause of death among the elderly, and the rate of death
increases with age. Changes in blood pressure regulation, cardiovascular function,
circulatory haemodynamics and lipid metabolism lead to CVD. In addition, stiff
arteries [McLeod et al. 2004] and endothelial dysfunction [Chan et al. 2003; Wu et
al. 2005] have been found in subjects with atherosclerotic heart disease.
1.1.1 Atherosclerosis
Atherosclerosis is a disease of large and medium-sized elastic arteries. It is
characterised by inflammation of the vascular wall, endothelial dysfunction and an
accumulation of cholesterol, lipids, calcium and cellular debris within the intima of
the vessel wall [Orford et al. 2005]. Plaque deposits may grow and obstruct the
lumen, or break-up and release material into the blood stream [Hansson 2005]. The
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presence of plaque can result in altered blood flow and cardiovascular remodelling,
which in turn may lead to myocardial infarction (MI), stroke, and peripheral vascular
disease. A number of interrelated processes contribute to atherosclerosis [Loscalzo
et al. 1996; Orford et al. 2005]. These include vascular dysfunction, smooth muscle
cell migration and proliferation, cellular inflammation, thrombogenicity of the blood
vessel wall, and activation of fibrinolysis and coagulation.
A popular theory of how atherosclerosis develops is the "response-to-injury" theory
whereby injury of endothelial cells leads to inflammation and fibroproliferation of
the vascular wall [Hansson 2005]. Factors that can lead to endothelial injury include
oxidized low-density lipoprotein (oxLDL) cholesterol, hyperglycaemia,
hyperhomocysteinemia and by-products of cigarette smoke [Ross 1999]. Circulating
monocytes infiltrate the intima of the vessel wall, and these tissue macrophages act
as scavenger cells, taking up low-density lipoprotein cholesterol (LDL-C) and
forming foam cells which are characteristics of the initial stages of atherosclerosis
[Berliner et al. 1995], Atherosclerosis is initially characterised by the development of
a fatty streak which is caused by the build-up of serum lipoproteins within the intima
of the vessel wall [Ross 1993]. Progressive build-up of lipid-rich macrophages, T-
lymphocytes, and the migration and proliferation of smooth muscle cells leads to the
development of a fibrous cap [Libby et al. 2005; Stary et al. 1994]. In addition,
reduced endothelium-derived nitric oxide (NO) bioavailability increases proliferation
and leads to plaque maturation.
Atherosclerotic plaques have an increased tendency to occur at points where there is
branching of blood vessels and high curvature [Ross 1999]. They are also more
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likely to occur at areas of geometric irregularity in blood vessels and at points where
there are sudden changes in blood velocity or direction of flow [Stary et al. 1992]. In
particular, atherosclerosis is most commonly found in the coronary arteries, the
major branches of the thoracic and abdominal aorta, and the large conduit vessels of
the lower extremities [Glagov et al. 1992].
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1.2 ARTERIAL STIFFNESS
Arterial stiffness describes the rigidity of the arterial walls. About 2,000 B.C. the
famous Chinese "Yellow Emperor" Huang Ti noted an association between salt and a
"hardened pulse" [He et al. 2002], In 1827 Bright described a relationship between
the hardening of arteries, albuminuria, cardiac hypertrophy and the risk of death from
stroke and cardiac failure [Nichols et al. 1998], Fifty years later Mahomed
[Mackenzie et al. 2002; Nichols et al. 1998] was the first to describe changes in the
contour of the arterial pressure pulse with age and in patients with hypertension. He
noted that hypertensives and older people had an increase in the amplitude of the late
systolic peak and little or no diastolic variation. This is illustrated in Figure 1-1. In
1922 Bramwell and Hill [Nichols et al. 1998] carried out the earliest in-vivo studies
in which they made non-invasive assessments of the wave foot of sphygmograms to
calculate pressure pulse wave velocity. This technique re-emerged in the late 1970's.
In healthy people, stiffening of the arteries with age is accompanied by an isolated
elevation in systolic blood pressure (SBP), which averages 25-35 mmHg between the
third and eighth decades of life [Nichols et al. 1998], This increase in arterial
pressure after-load affects cardiac function. For example, many individuals between
the third and ninth decades have an increase in their left ventricular mass which may
be partly due to increased arterial pressure and/or vascular stiffness. This has
important implications as left ventricular hypertrophy has been shown to be a major
independent risk factor for morbid cardiovascular events including MI and cardiac













Figure1-1Pressurep lswav sinel sticandtiffrte i . (a)Inormalelasticorta,blo disjectedwi hcc rdi cst okenmalla untretainedythdu gystol .Whe theelasticaor arecoils,t issmallv lumefblo di pr pelledforwardntperipheralcirc l t onnackw dt nary arteriesduringias ol ,(b)Stiff ingoftho tacauseslosela t cecoilandincr asev scul resistancewh chn resultsinmostofthestr kevol mb ingprop ledtcirc la ionduringsystolewi hred cfl wiasto .Ainc a resistanceal ole dstoinc eashecardiacworkr qui edithchst okv l m . 25
1.2.1 Physiology of the arteries
The arterial wall comprises three layers: the tunica intima, the media and the
adventitia [Loscalzo et al. 1996; Nichols et al. 1998], This is illustrated in Figure
1-2. In simple terms, the tunica intima comprises an elastic membrane lining and
smooth endothelium [Loscalzo et al. 1996]; the tunica media comprises elastic fibres
and smooth muscle cells; and the tunica adventitia comprises connective tissue,
elastin and collagen fibres. The distribution of elastin and collagen varies along the
aorta [Nichols et al. 1998]. Elastin is the main component in the proximal aorta,
whereas in the distal aorta, the collagen-to-elastin ratio is reversed with collagen
being more dominant in the peripheral arteries [Avolio et al. 1998; Nichols et al.
1998]. Elastic fibres in the aorta form thick concentric lamellae in the tunica media
with interlaminar connecting fibres scattered radially through the vessel wall
[Arteaga-Solis E et al. 2000] whereas collagen fibres are arranged circumferentially
[Nichols et al. 1998]. Several neurohumoral factors, for example angiotensin II and
aldosterone, modulate collagen accumulation [Zieman et al. 2005]. Chemical
modification of collagen, through processes such as breakdown, cross-linking, or
protein glycation can cause an increase in arterial stiffness [Tayebjee et al. 2003].
Irregular distribution of collagen along the vascular wall results in discontinuities in
their distribution along the walls mainly at vessel bifurcations.
The high elastin-to-collagen ratio in the walls of the large arteries allows them to
expand and recoil with pulsatile flow [Loscalzo et al. 1996], This ratio decreases
towards the periphery. Arteries are found to stiffen with age due to an accumulation
of fibre, intimal and medial thickening, calcium deposits in the extracellular matrix
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(ECM) and breakdown of the elastic laminae [London 1995]. These changes are
more commonly found in the aorta and are caused by cyclical stress over time. The
diameters of the common carotid artery, abdominal aorta, femoral artery, and
brachial artery are known to increase with age. However, the percentage change in
diameter is found to decrease [Bortolotto et al. 1999a],
The elasticity of a given vascular segment is determined by its distending pressure
which is, in turn, determined by mean arterial pressure (MAP) [Bank et al. 1996]. An
increase in the distending pressure causes an increase in the recruitment of the
inelastic collagen fibres which leads to a decrease in vascular elasticity [Lakatta et al.
2003]. Collagen and elastin are connected by smooth muscle cells. Therefore,
changes in smooth muscle tone can affect the contribution of collagen and elastin to
arterial stiffness. Smooth muscle tone is affected by the nervous system, hormones,



















Figure 1-2 The arterial wall.
Schematic of an artery and its constituent layers: the tunica intima, tunica media and
tunica adventitia. The tunica intima comprises a layer of endothelial cells lined by an
elastic membrane. The tunica media comprises elastic fibres and smooth muscle cells
while the tunica adventitia comprises connective tissue, elastin and collagen fibres.
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1.2.2 Arterial system
The oldest model of the arterial system is the Windkessel system [Nichols et al.
1998]. This system is analogous to the inverted air-filled dome of a fire engine which
works by changing pulsatile flow from a hand activated pump into a steady stream.
The Windkessel theory models the circulation as a central reservoir (the large
arteries) into which the heart pumps, and from which blood travels to the tissues
through non-elastic conduits (peripheral arteries). It is now well known that during
the systolic component of pulsatile flow, energy is absorbed by the large elastic
arteries. This leads to a reduction in the work the heart requires to propel blood
forward [London 1995].
1.2.3 Arterial pressure waveform
The arterial pressure waveform is a composite of the forward and reflected pressure
waves created by ventricular contraction [Glasser et al. 1997]. Pressure waves are
mainly reflected from branch points or junctions between low resistance conduit
arteries and high resistance arterioles. This leads to changes in the arterial pressure
waveform as shown in Figure 1-3. Other factors play an important role, for example,
differences in arterial properties between two sites and the presence of arterial
lesions. In elastic vessels the reflected waves arrive back at the aortic root during
diastole and this augments diastolic pressure thereby improving coronary artery
perfusion. As vessels become stiffer the velocity of the pressure wave increases
[Nichols et al. 1998]. This leads to the reflected wave arriving earlier at the central
arteries and augmenting SBP with a consequent decrease in diastolic blood pressure
(DBP). Arterial stiffness also causes an increase in the amplitude of the reflected
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wave which further augments central SBP. Pulse pressure (PP), a surrogate measure
of arterial stiffness, is an independent predictor of cardiovascular mortality, and is a
stronger predictor than either SBP or DBP in older subjects [Franklin et al. 1999].
Recent data have shown arterial stiffness to be an additional and independent risk
factor [Blacher et al. 1999b],
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1.2.4 Measuring arterial stiffness
There are various methods of measuring arterial stiffness. A number of techniques
give information on systemic arterial stiffness, while others give information on local
stiffness of a particular vessel.
1.2.4.1 Pulse pressure
The blood pressure waveform with time is an interaction between the steady
component ofmean arterial blood pressure (MAP) and the pulsatile component of PP
[Safar et al. 2003]. PP is the difference between SBP and DBP by intermittent
ventricular ejection from the heart. PP is influenced by several cardiac and vascular
factors, for example, cardiac output, large-artery stiffness and wave reflection [Safar
et al. 2003]. Both SBP and DBP increase with age [Franklin et al. 1997]. However,
beyond the age of 50-60 years DBP begins to decline. PP has been shown to increase
with age and may be the best index of cardiovascular risk amongst the various
components [Franklin et al. 1999]. In 1922 Bramwell and Hill recognised PP as a
valuable surrogate marker of arterial stiffness.
Peripheral PP can be readily measured using a standard sphygmomanometer
[Mackenzie et al. 2002] and is one of the simplest surrogate measure of arterial
stiffness. However, measurement of PP alone is not an accurate measure of arterial
stiffness. This is because the pressure wave is amplified as it travels from the aorta to
the periphery and therefore PP measurements in the periphery may not accurately
show changes in the central arteries [Nichols et al. 1998]. This is illustrated in
Figure 1-4.
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Central PP may be a more accurate predictor of risk than peripheral PP as the former
contributes most to the development of left ventricular hypertrophy and it is also a
predictor of cardiovascular mortality [Deague et al. 2001]. In addition, carotid intima
medial thickness, a marker of cardiovascular risk [Simons et al. 1999], is more
closely associated with carotid rather than brachial PP [Boutouyrie et al. 1999;
Mackenzie et al. 2002],
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Figure 1-4 Pressure waves in the central and peripheral arteries.
Schematic of changes in pressure waveforms as pressure waves travel towards
peripheral arteries. The waveform for each arterial site describes the interaction of
the incident and reflected pressure waves. (Adapted from Nicholls WW, O'Rourke
M. McDonald's Blood Flow in Arteries: Theoretical, Experimental, and Clinical
Principles. 1998)
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1.2.4.2 Pulse wave velocity
Pulse wave velocity (PWV) is the speed at which the forward pressure wave is
transmitted from the aorta through the vascular tree [Safar et al. 2003], It is
calculated by measuring the time taken for the arterial waveform to pass between two
points a measured distance apart (Figure 2.2 and 2.3). This can be carried out by
taking readings from the two sites simultaneously, or "gating" separate recordings to
a fixed point in the cardiac cycle, usually the R wave of the ECG [Wilkinson et al.
2004], The foot-to-foot methodology is most commonly used to detect the start of a
waveform as this avoids the confounding influence ofwave reflection [Mackenzie et
al. 2002; Wilkinson et al. 1998]. PWV is calculated as an average of 10 consecutive
waveforms. There is an increase in PWV with age. This increase is larger in the aorta
then in peripheral vascular beds. This is due to a greater disorganisation of the
arterial media in central elastic arteries. The elastic arteries are prone to fatigue and
fracture of elastin fibres as a consequence of greater pulsatile strain [Avolio AP et al.
1985; Avolio et al. 1983].
Invasive and non-invasive methods can be used to measure characteristics of either
the pressure or flow waves. PWV has been shown to increase with stiffness
according to the Moens-Korteweg equation, PWV= y[(Eh/2pR), where E is Young's
modulus of the arterial wall, h is wall thickness, R is arterial wall radius at the end of
diastole, and p is the density of blood [Nichols et al. 1998], From this equation we
know that PWV increases in narrower blood vessels as seen in the peripheral blood
vessels. The aorta and its first branches are responsible for most of the
pathophysiological effects found in stiffer arteries. Therefore, PWV is most
35
commonly measured from differences in pulse wave travel in the carotid and femoral
arteries to give a measure of central aortic stiffness.
The technique of PWV has been validated and is reproducible. The principle is
relatively simple and the technique can easily be learnt and applied in both a research
and clinical setting. Moreover, outcome data show that PWV is an independent
predictor of cardiovascular risk in both patients with hypertension [Blacher et al.
1999a] and those with end-stage renal disease [Blacher et al. 2003], Measurements
of the pressure wave can be made non-invasively and estimated measures of the
distance travelled by the pressure wave can be made from the body surface. The
PWV measurements become less accurate, however, if the recording points are very
close together, and the technique is, therefore, limited to use on larger arteries. PWV
is a measure of a distinct pathway through the vascular system rather than systemic
arterial stiffness.
1.2.4.3 Ultrasound
Ultrasound is another method ofmeasuring arterial stiffness, but its use is limited to
the larger and more accessible arteries [Mackenzie et al. 2002], This technique is
commonly used in the brachial, femoral and carotid arteries and the abdominal aorta,
and distensibility or compliance measurements are recorded. Images of the vessel
wall are captured with each cardiac cycle, and the maximum and minimum cross-
sectional areas of the vessel are calculated [Mackenzie et al. 2002], One of the
benefits of ultrasound imaging is that it is a non-invasive technique. However, there
are some limitations to its use. One such limitation is that the bulky machines are not
portable. There are also difficulties in detecting small changes in vessel diameter due
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to its limited resolution (minimum scatter spacing at which it can discriminate
closely spaced scattered echoes) with changes in graduations detectable to 0.1 mm.
In addition, operators need to be trained to image blood vessels accurately. Blood
pressure measured simultaneously with ultrasound imaging is usually carried out in
the brachial artery or finger [Oliver et al. 2003]. This may not be an appropriate
measure of blood pressure due to the phenomenon of pressure wave amplification
especially when assessing distensibility of the central arteries [Oliver et al. 2003],
1.2.4.4 Magnetic resonance imaging derived indices
Magnetic resonance imaging (MRI) is a non-invasive technique that measures
vascular distensibility and compliance [Mackenzie et al. 2002], Most MRI studies
carried out on humans have involved taking measurements from the aorta. Studies
using MRI have shown age to be inversely proportional to aortic distensibility and
aortic distensibility has been shown to be lower in hypertensive patients [Mackenzie
et al. 2002; Resnick et al. 1997], In addition, arterial compliance, as measured by
MRI, has been shown to be lower in patients with CAD [Mohiaddin RH et al. 1989].
The MRI machine is very expensive and provides more detailed images than
ultrasound imaging. MRI scanners are not portable and patients need to be placed
inside them even though only a small part of the body is being assessed. This makes
them unsuitable for use in a clinical setting as a test of endothelial function
[Mackenzie et al. 2002],
1.2.4.5 Arterial waveform analysis
Numerous methods of analysing the arterial waveform have been developed
including the vasculograph and, more recently, non-invasive applanation tonometry.
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Arterial pressure or blood volume waveforms can be analysed to measure arterial
stiffness.
1.2.4.5.1 Arterial pressure waveform analysis
In healthy people, the reflected pressure wave returns during the diastolic phase
[Nichols 2005; Yasmin et al. 1999]. However, an increase in PWV causes the
forward wave to be transmitted quicker. This leads to the reflected wave returning
earlier and augments the forward wave during systole [O'Rourke et al. 2004]. Early
wave reflection distorts the favourable shape of the ascending aortic pressure wave
causing a relative increase in pressure during systole and a relative decrease in
pressure during diastole. This early wave reflection distorts arterial function, not only
by increasing aortic and left ventricular pressure but also by decreasing aortic
pressure during diastole [Nichols 2005],
Peripheral artery pressure can be measured using the technique of applanation
tonometry [Nichols et al. 1998]. The arterial pressure waveform is calibrated to
measure brachial blood pressure. Peripheral pressure wave analysis can be used to
derive the central aortic waveform from a peripheral artery, for example the radial
artery using a validated transfer function [O'Rourke et al. 1996; Pauca et al. 2001],
From the derived central aortic waveform, an average of 10 consecutive waveforms,
the augmentation index (AIx) can be calculated [Nichols el al. 1998], AIx is the
proportion of central PP that results from arterial wave reflection and is used as a
measure of systemic arterial stiffness as shown in Figure 1-5. AIx is determined by a
number of factors including the PWV, intensity ofwave reflections, and the elasticity
and diameter small muscular arteries [O'Rourke et al. 2004].
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Applanation tonometry is a simple non-invasive technique. The tonometer is the size
of a pen which is connected to a personal computer. It is a portable system, which
makes it suitable for use in both clinical and research settings. It is a useful technique
whereby characteristics of blood pressure in the central arteries can be determined
[Pauca et al. 2001], It also allows continuous measurements, which makes it a useful
tool for investigational drug studies. One of the main limitations of this technique is a
generalised transfer function is used to derive central parameters from peripheral
parameters [Oliver et al. 2003]. The pressure applied through the tonometer and the
angle at which it is held can affect the shape and quality of the pressure waveforms,
which in turn will affect the calculation of augmentation indices.
Pressure pulse contour analysis is another method ofmeasuring arterial stiffness non-
invasively [Cohn et al. 1995; McVeigh et al. 1999], which involves tonometry of the
radial artery. However compliance is derived using a modified Windkessel model of
the circulation and an assessment of the diastolic pressure decay. This method can be
used to measure large-vessel and peripheral compliance. Pressure waveform analysis
can also be carried out, more distally, using a servocontrolled pressure cuff on the
digital artery as in the Finapres system [Millasseau et al. 2000].
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Time
Figure 1-5 Central pressure waveform.
A schematic of a central pressure waveform from which the augmentation index can
be calculated. The augmentation index is calculated as the difference between peaks
P2 and P\ (AP) and this is expressed as a percentage of the PP. If is the foot of the
wave, and Tr is the time between 7f and the point of inflection.
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1.2.4.5.2 Digital volume pulse waveform analysis
The digital volume pulse (DVP) waveform can be recorded using the technique of
photoplethysmography [Chowienczyk et al. 1999]. The blood volume pulse
waveform has similar characteristics to the pressure pulse waveform [Millasseau et
al. 2000]. This technique resembles that of pulse oximetry, where a small infra-red
light transmitting device is attached to the index finger and an averaged waveform is
produced from a recording of 10 consecutive waveforms. The DVP is formed as a
result of the pressure wave transmitted (systolic component) along a direct path from
the aortic root to the finger [Millasseau et al. 2000]. The second part of the
waveform is formed by a pressure wave which has been transmitted from the
ventricle along the aorta to the lower body, and reflected back along the aorta to the
finger (diastolic component). The dichrotic notch is produced by the overlapping of
the incident and reflected waves and is associated with either the second peak or the
point of inflection of the overlapping waves [Chowienczyk et al. 1999], The timing
of the diastolic component relative to the systolic component depends on the PWV of
the pressure waves in the large arteries and aorta. The height of the subject is
divided by the time between the first peak and the dichrotic notch to obtain a
stiffness index (SI) [Millasseau et al. 2002] which has been shown to strongly
correlate with aortic PWV [Millasseau et al. 2000] (Figure 2.4). The reflection index
(RI) is the height of the second peak of the DVP expressed as a percentage of the
waveform peak and is a measure of the tone of the small or medium arteries.
The DVP technique has the advantages of being relatively simple, less operator-
dependent, less expensive and more portable. The photoplethysmogram is able to
reject ectopic beats and artefacts while recording fast sequential measurements. The
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photoplethysmographic technique is, however, affected by damping of the peripheral
pulse and temperature-dependent changes in the peripheral circulation. A study
[Bortolotto et al. 2000] comparing photoplethysmography of the finger with PWV
found the latter to correlate more closely with those parameters which influence
vascular compliance, namely age and atherosclerosis. Further work is therefore
needed to verify the relationship between the DVP and central pressure waveforms.
1.2.4.6 Reproducibility ofPWV, AIx and DVP
1.2.4.6.1 PWV
Arterial stiffness assessed non-invasively by measurement of pulse wave velocity
(PWV), is a simple and reproducible method. This was shown by Wilkinson et al.,
who carried out a reproducibility study of aortic and brachial PWV in 24 subjects (10
controls, 8 hypertensives, and 6 hypercholesterolaemics), with a mean age of 40
years [Wilkinson et al. 1998], Measurements were made by 2 observers randomly at
least 2 minutes apart on the same day. From Bland-Altman plots the mean ± SEM
within-observer differences for aortic and brachial PWV were 0.07 ± 0.24 m/s and
0.14 ± 0.07m/s respectively (the SD of the differences for aortic and brachial PWV
was 1.17 m/s and 0.82 m/s respectively; P=0.78). The mean ± SEM between-
observer difference was -0.30 ± 0.26 m/s and -0.44 ± 0.23 m/s for aortic and brachial
PWV (the SD of the differences for aortic and brachial PWV was 1.25 m/s and 1.09




The reproducibility of AIx was analysed in a group of 33 subjects (5 controls, 12
diabetics and 16 hypertensives) with a mean age of 51 years [Wilkinson et al. 1998].
The mean ± SEM within-observer difference was found to be 0.49 ± 0.9% (P=0.36)
and the between-observer difference, 0.23 ± 0.7% (P=0.73). The SD of the within-
observer differences was 5.37% while the difference for between-observers was
3.80%. This showed AIx to be reproducible not only over time but also between two
different operators.
1.2.4.6.3 DVP
A generalised transfer function has been derived by Millasseau et al. that predicts the
pressure pulse from the volume pulse across a wide age range in both normotensive
and hypertensive subjects [Millasseau et al. 2000]. The transfer function can be
applied to predict the pressure pulse after GTN administration, when large changes in
volume and pressure are seen. They went on to show [Millasseau et al. 2002] that SI
correlated strongly with carotid-femoral PWV, as measured using applanation
tonometry, and that both the SI and PWV correlated independently with age and
blood pressure. This indicates that both the SI and PWV are influenced by similar
factors.
1.2.5 Arterial stiffness and cardiovascular function
In elastic arteries the reflected pressure wave returns during the diastolic phase of
blood pressure and therefore enhances coronary blood flow. As large vessels stiffen,
the limited ability of the aorta to stretch means the reflected pressure waves arrive
earlier during systole resulting in a late systolic peak in arterial pressure. This
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process leads to larger systolic and PPs. Moreover, the heart has to work harder to
pump blood into the circulation against a higher pressure gradient. This has a
detrimental effect as it leads to left ventricular hypertrophy of the heart as it tries to
maintain cardiac stroke volume.
AIx has been shown to increase with both MAP [Wilkinson et al. 2001], and with
age [Kelly R et al. 1989], and it is inversely proportional to heart rate [Gatzka et al.
2001a]. AIx has also been shown to be higher in patients with risk factors for
atherosclerosis, such as patients with type I diabetes [Wilkinson et al. 2000b] and
hypercholesterolaemia [Wilkinson et al. 2002d], despite similar peripheral blood
pressure when compared to controls. In a study by London et al. a high carotid AIx
was found to predict mortality in patients who had normal PWV measures [London
et al. 2001]. This highlights the importance of assessing other characteristics of the
arterial pressure waveform. In young subjects peripheral arterial stiffness exceeds
central arterial stiffness. This is reversed, however, with increasing age. This is due
to a decrease in pressure wave amplification and reflection but an increase in harmful
forward pressure wave into the microcirculation [Mitchell et al. 2004b].
Development of arterial plaque can affect vascular function and lead to
atherothrombotic complications. It is known that plaque develops at locations of low
shear stress [Ross 1999], However, as the size of the plaque grows into the lumen it
is exposed to higher shear stress which can lead to destabilisation of the fibrous cap
and plaque rupture [Hansson 2005]. The shoulder regions of the plaque are especially
vulnerable to rupture. In addition, pulsatile stress can cause plaque instability. Lovett
et al. have shown PP to positively correlate with carotid plaque rupture and plaque
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ulceration [Lovett et al. 2003]. Therefore, an increase in PP due to the stiffening of
large arteries can lead to plaque destabilisation and rupture.
1.2.6 Arterial stiffness and cardiovascular risk
An increase in arterial stiffness may have several important consequences. An
increase in PP or aortic stiffness is associated with an increase in the risk of
coronary events, stroke, all-cause and cardiovascular mortality [Blacher et al. 1998;
Domanski et al. 1999; Gatzka et al. 1998; Laurent et al. 2001; Mitchell et al. 1997].
Arterial stiffness measured by PWV, carotid elastic modulus, or the ratio of stroke
volume to PP, independently predicts all-cause and CVD mortality in patients with
end-stage renal failure (ESRF) and essential hypertension [Asmar et al. 1995;
Blacher et al. 1998; Laurent et al. 2001]. In addition, brachial PP has been shown to
be an independent risk factor for CHD and is associated with all-cause and CVD
mortality [Benetos et al. 1997], However, brachial PP is an indirect index of stiffness
of the large central arteries to PP amplification [Franklin et al. 1999; Nichols et al.
1998; O'Rourke et al. 1999]. This is supported by findings in which central PP
determines left ventricular load [Saba et al. 1993] and is associated with the degree
of carotid intima-media thickness [Boutouyrie et al. 1999], which is itself a predictor
of cardiovascular risk. In addition, central arterial stiffness has been shown to be
higher in patients with CAD, diabetes mellitus, stroke, hypertension,
hypercholesterolaemia and ESRD [Laurent et al. 2001; Laurent et al. 2003; Schram
et al. 2004; Weber et al. 2004; Wilkinson et al. 2002d].
In newly diagnosed patients with CAD a higher left ventricular mass and stiffer
proximal aorta, as measured by echocardiography, has been found compared to
45
control subjects [Gatzka et al. 1998]. Moreover, Hirai et al. have shown in patients
with a previous MI and who have a higher number of diseased coronary blood
vessels to have higher proximal aortic stiffness [Hirai T et al. 1989]. More recently,
by measuring AIx, London et al. showed arterial wave reflections to be a major
predictor of mortality in ESRF patients [London et al. 2001], These results were
further supported by others who found that patients with CAD and early wave
reflections had stiffer arteries. Early wave reflections were also found to be related to
the severity ofCAD, particularly in patients less than 60 years of age [Nurnberger et
al. 2002; Weber et al. 2004],
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1.3 ENDOTHELIAL FUNCTION
The endothelium plays an important role in regulating vascular tone and blood flow
through the arteries. Endothelial function and the release of endothelium-derived
factors are necessary to maintain and regulate tissue perfusion pressure. In 1980,
work by Furchgott & Zawadski showed that relaxation of blood vessels by
acetylcholine requires the presence of endothelial cells. Ach acts on muscarinic
receptors, on these endothelial cells, and causes the release of a substance resulting in
vascular smooth muscle relaxation [Furchgott et al. 1980], The vasodilator produced
by the endothelium in response to Ach was named 'endothelium derived relaxing
factor' which was later identified as NO [Palmer et al. 1987]. More recently, studies
have shown the presence of abnormal endothelium-dependent vasomotion in patients
with atherosclerosis and its associated risk factors [Bonetti et al. 2003; Brunner et
al. 2005]. Abnormalities in endothelial function are now known to be an early
pathophysiological manifestation of hypertension, diabetes and atherosclerosis
[Gimbrone 1999],
1.3.1 THE ENDOTHELIUM
The endothelium is a single cell thick layer which lines the lumen of blood vessels.
In total, the endothelial lining weighs -1.8 kg and has a surface area of -700 m3
[Luscher et al. 1997], The endothelial lining cells are ideally positioned to directly
influence cells within the vessel wall and circulating blood components. The
endothelium regulates a large number of processes, for example, smooth muscle cell
proliferation, production of free radicals, platelet aggregation, leukocyte adhesion,
haemostasis, thrombosis, inflammation, and immune responses [Deanfield et al.
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2005; Widlansky et al. 2003]. Vascular tone is controlled by endothelial cells via the
secretion of vasodilator substances, such as prostacyclin and nitric oxide (NO), and
contracting substances, such as endothelin. Vascular tone is also regulated by
norepinephrine, serotonin, inactivation ofbradykinin and conversion of angiotensin I
to angiotensin II.
1.3.2 Endothelial dysfunction
Endothelial dysfunction describes an impairment of the normal biochemical
processes carried out by endothelial cells. Endothelial dysfunction commonly
preceedes the development of coronary atherosclerotic lesions and thrombotic events
(e.g., acute myocardial infarction (AMI) and unstable angina) [Celermajer et al.
1992; Shah 1920]. Endothelial dysfunction is characterised by an impairment of
endothelium-dependent vasodilatation, inflammation, proliferation of smooth muscle
cells, and a procoagulatory state [Endemann et al. 2004],
NO is the main vasodilator released by the endothelium [Endemann et al. 2004], The
enzyme eNOS, which is stimulated by calcium, catalyses the conversion of L-
arginine to L-citruline and NO [Moncada et al. 1993]. NO activates soluble
guanylate cyclase, in the smooth muscle cells, which leads to an increase in cyclic
guanosine 5-monophosphate (cGMP) and subsequent vasodilatation of the arterial
wall. This is illustrated in Figure 1-6. NO is responsible for inhibition ofmonocyte-
endothelium cell interactions, smooth muscle cell proliferation and migration, and
platelet activation. Other relaxing factors include endothelium derived
hyperpolarising factor (EDHF), prostacyclin, C-type natriuretic peptide, 5-
hydroxytryptamine (serotonin; 5-HT), adenosine triphosphate (ATP), substance P,
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and acetylcholine [Shepherd 1995; Shimokawa 1999], The endothelium also
releases contracting factors like endothelin-1 (ET-1), angiotensin II, thromboxane
A2, prostaglandin H2, superoxide anions, and ATP [Endemann et al. 2004], Basal
release of NO has been found in both conduit and resistance vessels in the human
coronary circulation [Quyyumi et al. 1995], Basal vascular tone is also likely to be
mediated by endothelin, angiotensin II and prostacyclin [Harris et al. 2004]. Basal
blood flow is another factor that can influence vascular tone. An increase in blood
flow promotes a continuous release of endothelium-derived relaxing factors
[Bassenge et al. 1988] while the presence of hypoxia, thrombin, norepinephrine and






























Figure 1-6 The vascular endothelium and smooth muscle cells.
Schematic of the interaction between the vascular endothelium and smooth muscle
cells in regulating vascular tone. In normal coronary arteries infusion of Ach causes
vasodilatation, however, in the presence of endothelial dysfunction Ach acts directly
on the smooth muscle cells and causes vasoconstriction. CPT denotes cold pressor
test; eNOS, endothelial nitric oxide synthase; GC, guanyl cyclase; GTP, guanosine
triphosphate; cGMP, cyclic guanosine monophosphate; L-NMMA, NG-monomethyl-
L-arginine; and MS; mental stress; NO, nitric oxide. Adapted from Tousoulis et al.
Evaluating endothelial function in humans: A guide to invasive and non-invasive
techniques.2005 [Tousoulis et al. 2005]
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1.3.3 Assessment of endothelial function
Endothelial function is measured by exposing blood vessels to an endothelium-
dependent vasodilating stimulus followed by measurement of the vasodilatory
response. Endothelial function of the coronary circulation is assessed by invasive




Coronary artery endothelial function is commonly assessed by intracoronary infusion
of acetylcholine (ACh), which acts on muscarinic receptors found on endothelial
cells, causing the release of NO and consequently dilatation of the coronary artery
[Tousoulis et al. 2005]. Acetylcholine dilates normal coronary arteries. However, in
patients with risk factors for atherosclerosis, and those with CAD, infusion of
acetylcholine results in an impaired vasodilatory response or paradoxical
vasoconstriction [Tousoulis et al. 1998; Widlansky et al. 2003]. Other vasoactive
substances that can be used as a test of coronary endothelial function include
bradykinin, serotonin and substance P.
1.3.3.1.2 Intrabrachial infusions
Endothelial function in the coronary arteries has been shown to closely correlate with
peripheral endothelial function [Jambrik et al. 2004], Intrabrachial infusion of
vasoactive agents, such as ACh and sodium nitroprusside, are used as endothelium-
dependent vasodilators [Deanfield et al. 2005] and endothelium-independent
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vasodilators respectively. Forearm blood flow (FBF) can be measured using strain-
gauge plethysmography or FMD via measurement of change in brachial artery
diameter ultrasound. Both these methods are described in detail in Sectionl.3.3.2.1
and 1.3.3.2.2. This methodology has fewer complications compared to intracoronary
infusions and the brachial artery is easily accessible in comparison to the coronary
arteries.
The disadvantage of using an invasive technique to assess endothelial function is the
risk associated with invasive procedures and the cost/complexity of carrying out
invasive tests. Invasive endothelial function testing, especially intracoronary vascular
function testing, is not an appropriate screening tool in a clinical setting. This has led
to the development of non-invasive techniques of evaluating endothelial function
[Kuvin et al. 2003].
1.3.3.2 Non-invasive techniques
Non-invasive techniques ofmeasuring peripheral endothelial function testing provide
an opportunity to evaluate large patient populations. Various non-invasive techniques
available are discussed below.
1.3.3.2.1 Flow mediated dilatation
High-resolution ultrasound, to image the brachial artery during reactive hyperaemia,
can be used to assess peripheral vascular function [Anderson et al. 1995b]. This
technique measures FMD. [Corretti et al. 2002; Sorensen KE et al. 1995]. Arterial
blood supply is interrupted by the use of a cuff inflated to suprasystolic pressure
which causes ischaemia of the forearm. Release of the cuff induces reactive
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hyperaemia (which is an increase in blood flow due to increased shear stress) causing
an increase in NO production and consequent vasodilatation of the brachial artery.
Endothelial function is measured as the magnitude of the change in vessel diameter
from the baseline period to the peak during reactive hyperaemia [Landmesser et al.
2002; Rubenfire et al. 2000; Rubenfire et al. 2002],
1.3.3.2.2 Strain-gauge plethysmography
Another non-invasive method of assessing endothelial function is the evaluation of
changes in FBF to hyperaemia [Tousoulis et al. 2005], Changes in FBF to reactive
hyperaemia represents endothelium-dependent vasodilatation whereas changes in
FBF to GTN represents endothelium-independent vasodilatation. Vasodilatation due
to hyperaemia and GTN is calculated as the percentage change in flow from baseline
to maximum flow. Strain-gauge plethysmography does not require highly trained
personnel compared to assessment ofFMD.
1.3.3.2.3 Arterial wave reflections
Newer non-invasive techniques of assessing endothelium-dependent vasodilatation in
the peripheral circulation include applanation tonometry or finger photo-
plethysmography. Administration of vasodilators, such as glyceryl trinitrate, have a
profound effect on the pressure waveform, reducing wave reflection, augmentation
index, central systolic pressure and arterial stiffness, without causing detectable
changes in peripheral vascular resistance or peripheral blood pressure [Kelly RP et
al. 1990]. Salbutamol, a /32-adrcnergic receptor agonist, has been shown to lower
both the inflection point of the DVP measured by finger photoplethysmography
[Chowienczyk et al. 1999] and AIx measured by applanation tonometry [Wilkinson
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et al. 2002b], These actions of salbutamol are mediated, at least in part, through the
NO pathway [Dawes et al. 1997; Hayward et al. 2002], Furthermore, in patients with
hypercholesterolaemia, who are known to have impaired endothelial function, the
effect of salbutamol on AIx was blunted. This finding correlated with acetylcholine-
induced vasodilatation in the forearm using strain gauge plethysmography
[Wilkinson et al. 2002b], Patients with CAD have also been found to have a smaller
decrease in AIx after the administration of salbutamol when compared with healthy
controls [Hayward et al. 2002],
1.3.4 Endothelial dysfunction and cardiovascular function
Changes in one or more functions of the endothelium can lead to endothelial
dysfunction. The endothelium, for example, may cause oxidation of low-density
lipoprotein (LDL) [Ohara et al. 1993] which, when produced, can directly injure the
endothelium [Ross 1993]. Endothelial injury promotes the development of
atherosclerosis by increasing the adhesiveness of platelets, monocytes and T-
lymphocytes to the endothelium. Endothelial injury also causes an increase in the
permeability of the endothelial layer and increases production of cytokines [Ross
1999]. Monocytes and lymphocytes enter the intima of the artery. The monocytes are
activated to macrophages which absorb the oxidised LDL (oxLDL) and form foam
cells. An increase in vasoconstrictors, such as endothelin and angiotensin II, cause
further damage by promoting smooth muscle cell proliferation which leads to the
development of plaque [Drexler 1998], Therefore, the presence of endothelial
dysfunction is an indicator of the presence of vascular damage even though structural
changes may not be apparent [Davignon et al. 2004],
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Endothelial function is affected by many factors [Cooke JP 1997; Drexler et al.
1999; Minor R.L.Jr et al. 1990; Russo et al. 2002], including higher LDL
concentrations [Anderson et al. 1995a], higher plasma homocysteine concentrations
[Stuhlinger et al. 2001], presence of hypertension [Panza JA et al. 1990]or diabetes
mellitus [Tilton et al. 1997], oestrogen deficiency [Taddei et al. 1996], and increase
in free radicals due to smoking [Celermajer DS et al. 1993]. Impairment of
endothelial-dependent vasodilatation can be caused by a decrease in NO production,
a decrease in NO bioavailability, an increase in oxidative stress or a decrease of
EDHF [Bolad et al. 2005; Cai et al. 2000], Vascular aging, for example, is
associated with a decrease in endothelium-dependent relaxations which may, in part,
be related to a decrease in basal and stimulated release of NO, or a reduced
expression of the endothelial synthase gene [Barton et al. 1997; Tschudi et al. 1996].
A number of interventions have been shown to restore endothelium-dependent
vasodilatation such as lipid lowering therapy, angiotensin converting enzyme (ACE)
inhibitors, antioxidants, anti-hyperglycaemia, diet and exercise [Davignon et al.
2004]. Statins, for example, have been shown to improve vasodilatation of the
coronary arteries [Treasure et al. 1995]. Statins are known to decrease production of
ET-1 and to increase endothelial nitric oxide synthase (eNOS) expression [Mraiche
et al. 2005]. Oestrogen therapy in post-menopausal women has also been found to
improve endothelial function [Guetta et al. 1997], Infusion of intracoronary estradiol,
in postmenopausal women with atherosclerosis or CAD, enhanced ACh-induced
coronary blood flow. This is thought to be due to an increase in the bioavailability of
NO.
55
Although a number of drugs have been shown to improve endothelial function in
experimental studies, these have not always been translated in-vivo. In addition,
several approaches have been shown to improve endothelial function and
cardiovascular risk, but not consistently. For example, various oestrogen [Gerhard et
al. 1998] and antioxidant [Timimi et al. 1998] preparations have been shown to
improve endothelial function. However, they have not shown any improvement in
patient outcomes [The Heart Outcomes Prevention Evaluation Study Investigators
2000], Atherosclerosis is, however, a multifactorial disease and other causative
factors may obscure any positive benefits of a particular drug therapy. In addition,
the inability of drugs to work at relevant sites, for example, the inability of
antioxidants to work at the vessel wall, may be misinterpreted as being ineffective.
1.3.5 Endothelial dysfunction and cardiovascular risk
Endothelial dysfunction in untreated hypertensive patients has been shown to be a
marker of future cardiovascular events, even after adjustment of risk factors for
atherosclerosis [Perticone et al. 2001b]. This study highlights the relationship
between endothelial dysfunction and cardiovascular events in patients who have risk
factors for atherosclerosis. Studies have also demonstrated that treatment of
cardiovascular risk factors, known to lead to endothelial dysfunction, is associated
with a decrease in cardiac events [Pedersen 2004], Endothelial dysfunction may lead
to cardiac events due to myocardial ischaemia in the absence of CAD [Hasdai et al.
1997; Zeiher et al. 1995]. Acceleration of coronary atherosclerosis, due to
endothelial dysfunction, can result in obstructive CAD and lead to cardiac events
[Hansson 2005],
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In a study, by Suiwaidi et al., subjects with CAD who had impaired endothelial
function were found to be more likely to experience cardiovascular events than those
subjects with normal endothelial function or mild dysfunction [Suwaidi et al. 2000],
These findings were supported by another study [Schachinger et al. 2000] in which
patients with poor coronary endothelial function experienced a larger number of
cardiovascular events, mainly revascularisation procedures. Patients with poor
endothelial function comprised patients who had enhanced constrictor responses to
cold pressor testing and acetylcholine, and a lower flow-dependent dilatation and
nitroglycerin-induced vasodilatation. In addition, they found that patients who had
impaired endothelium-independent vasodilatation to GTN had a poor prognosis. This
indicates that impairment of smooth muscle function can contribute to a reduced
vasodilatation of the coronary arteries. Halcox et al. reported that epicardial and
microvascular coronary endothelial dysfunction predicted cardiovascular events,
including sudden cardiac death, MI, and cerebral infarction in patients with and
without CAD [Halcox et al. 2002b]. However, they did not find endothelium-
independent vasodilatation of the epicardial and microvascular arteries to be
predictive of cardiovascular events. These studies indicate that endothelial function
testing provides valuable prognostic information. However, some studies have shown
coronary endothelial function testing to be of no benefit [Asselbergs et al. 2004] .
Extending observations from coronary endothelial function studies, peripheral
endothelial function is predictive of future cardiovascular events. For example,
patients with impaired peripheral vasodilatory responses have been shown to
experience a larger number of cardiovascular events [Heitzer et al. 2001; Perticone et
al. 2001b], require revascularisation procedures, and impaired responses are
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predictive of postoperative outcomes even after correcting for other cardiovascular
risk factors [Neunteufl et al. 2000],
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1.4 ENDOTHELIAL FUNCTION AND ARTERIAL STIFFNESS
Arterial stiffness and endothelial dysfunction have been shown to co-exist in patients
with cardiovascular risk factors, for example in diabetes [De Vriese AS et al. 2000;
Wilkinson et al. 2000b] and smokers [Liang et al. 2001; Zeiher et al. 1995]. Both
arterial stiffness and endothelial dysfunction have also been found in children with
low birth weight [Martin et al. 2000], severe obesity [Tounian et al. 2001], and in
familial hypercholesterolaemia [Yacine et al. 2000],
Animal studies have demonstrated that the vascular endothelium contributes to the
regulation of arterial stiffness. For example, PWV has been shown to be higher with
the administration of L-monomethyl-A^-arginine (L-NMMA), due to the inhibition
of basal endothelial NO production [Wilkinson et al. 2002e]. L-NMMA has also
been shown to inhibit reductions in PWV with the administration of ACh, an
endothelium-dependent vasodilator [Wilkinson et al. 2002e], In addition, endothelin
(ET-1), a vasoconstrictor acting via the ETA receptor, has been shown to cause an
increase in PWV [McEniery et al. 2003]. Moreover, selective blockade of the ETA
receptor by BQ-123 led to a decrease in PWV. These studies highlight that arterial
distensibility is increased with an increase in NO bioavailability or a decrease in
endothelial-derived vasoconstrictors. In both of the above-mentioned studies drugs
infused through the catheter exposed the arterial segment under study to the drug.
However, infusion of drugs through the sheath did not expose the arterial segment to
the effects of the drug because this was placed distal to the pressure sensors. This
methodology allowed exclusion of indirect drug effects such as reflex activation and
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changes in blood flow. Moreover, the local administration of drugs did not alter
mean arterial pressure or heart rate therefore excluding any possible systemic effects.
Studies in vivo have shown that inhibition of basal NO production reduces brachial
artery elasticity [Kinlay et al. 2001] and increases AIx [Wilkinson el al. 2002a]. In
addition, administration of ACh reduces PWV of the iliac artery in healthy subjects
compared to patients with congestive heart failure (CHF). An increase in vessel wall
shear stress increases both endothelium-dependent vasodilatation and arterial
distensibility. However, these responses are impaired in CHF patients [Ramsey et al.
1995]. Moreover, drugs which reduce arterial stiffness have also been shown to
reduce endothelial dysfunction, for example, with the use of ACE inhibitors
[Joannides et al. 2001]. Impaired endothelial function and an increase in AIx have
been found in patients with growth hormone deficiency [Smith et al. 2002], Both
these measures improved, without any changes in blood pressure, with growth
hormone replacement therapy.
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1.5 ARTERIAL ELASTICITY AND SKIN ELASTICITY
Arteries are known to become stiffer, and are described as being less elastic, with
both age and disease. A decrease in elasticity of the skin is also found with
advancing age. It is of interest that both the arteries and the skin derive their
mechanical properties from the structural components elastin and collagen. A study
carried out by Uiterwaal et al. showed school children who had a lower PP to have
higher skin extensibility [Uiterwaal et al. 2003]. More recently, a study [Elvan-
Taspnar et al. 2005] in women with a history of pre-eclampsia showed them to have
both stiffer arteries and stiffer skin (reduced elasticity of the skin) compared to
controls.
Abnormalities in skin and vascular collagen have been found to occur in patients
with cervico-cerebral artery dissections, intracranial aneurysms and in patients with
heritable connective tissue disorders, such as Ehlers Danlos syndrome (EDS) Type
IV and pseudoxanthoma elasticum (PXE). Patients with spontaneous cervico-
cerebral artery dissections have ultra-structural defects in collagen fibrils and
fragmented elastic fibres within the reticular dermis, indicating the presence of
defects within the extra-cellular matrix of arteries and skin [Brandt et al. 2001]. In
addition, patients with intracranial aneurysms have been found to have alterations in
the connective tissue of the reticular dermis [Grond-Ginsbach et al. 2002], In patients
with EDS type IV there are defects in normal collagen cross-linking and reduced
collagen content, specifically type III collagen, and these patients typically feature
hyperextensible skin and easy rupturing of the large arteries [Pope et al. 1975].
Patients with PXE also feature increased elasticity of both the skin and arteries, for
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example, as seen in the carotid artery due to an increase in fragmentation of elastic
fibres and an accumulation of proteoglycans [Komet et al. 2004], These studies
indicate that stiffness of connective tissues occurs both in the arteries and the skin. If,
connective tissue changes in the skin represent stiffening of arteries and
cardiovascular risk, skin elasticity has the potential to be used as an external marker
of arterial elasticity and as a predictor of cardiovascular risk.
1.5.1 Structural composition of arteries
Large arteries (aorta, carotids, iliofemorals) are composed of both elastin [Avolio et
al. 1998] and collagen. In comparison the smaller muscular arteries (brachial, radial,
coronary, renal, and mesenteric arteries) consist of a lower elastin-to-collagen ratio
[Champion et al. 1998]. Both collagen and elastin give the aorta its tensile strength
and stiffness. Elastic lamellae, formed from elastin, are found between smooth
muscle cells while collagen, mainly Type I and Type III collagen, is found as a fine
meshwork which surrounds smooth muscle cells or as bundles between smooth
muscle cells and the elastic lamellae [Loscalzo et al. 1996]. On histological
examination the intima of stiffened vessels has shown increased collagen, broken
elastin molecules, abnormally distributed endothelial cells, and infiltration of
vascular smooth muscle cells, macrophages, and mononuclear cells [Johnson et al.
2001; Lakatta 2003; Zieman et al. 2005]. The ECM composition of arteries changes
with both age or blood pressure [Glagov et al. 1992; Lim et al. 2004b] with a
decrease in elastin and an increase in collagen causing blood vessels to become
stiffer [Johnson et al. 2001]. The physiological composition of arteries is described
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in detail in Section 1.2.1 and a more detailed schematic of the structure of an artery is

















Figure 1-7 Elastin and collagen in an artery.
Schematic of the structure of arteries and changes in the orientation of elastin in the
arterial wall when the artery is (a) relaxed and (b) dilated. Elastic fibres are folded in
concentric rings and are connected axially by elastin. Collagen and elastin fibres are
found in the medial layer. At low strains the elastin lamellae unfold allowing the
aorta to deform easily, whereas at higher strains collagen is sufficiently stretched for
it to take most of the stress.
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1.5.2 Structural composition of skin
The skin plays a vital role by regulating body temperature, preventing water loss,
synthesising chemicals, and excreting waste materials. The skin consists of three
layers: the epidermal, dermal and subcutaneous layers. This is illustrated in Figure
1-8. The epidermis is composed of stratified epithelial cells, keratinocytes,
melanocytes, and, Langerhans and Merkel cells. The dermis is a thicker layer
composed of supporting matrix or ground substance. It is the ECM that contains the
protein fibres elastin and collagen. The dermis also contains fibroblasts, mast cells
and histiocytes (monocyte/macrophage). The dermis has variable thickness in
different parts of the body. For example it is 5mm in thickness on the back and
thighs, and 1 mm on the eyelids.
In the skin, the mechanical and structural function is determined by collagen while
its elasticity is determined by elastin [Tzaphlidou 2004], The dermal layer of the skin
is composed of 2 layers: the papillary layer and the reticular layer. Collagen in the
reticular layer consists of about 70% Type I collagen and 15% Type III collagen
[Silver et al. 2001a]. These ratios are reversed in arteries [Champion et al. 1998].
Type I collagen has thick fibrils which are closely packed, whereas, Type III
collagen exists as loose network of thin striated fibrils. Both elastin and collagen are
more compact with advancing age due to a decrease in spaces between the fibres.
The elastic fibres are also fragmented, affecting the elastic recovery of skin, and























Figure 1-8 Schematic of the skin which consists of the epidermis, dermis and
hypodermis.
The dermis consists of elastin and collagen which gives skin its elasticity and
resilience. Collagen fibres in the skin are randomly arranged, and deform in the
direction of the applied stress.
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1.5.3 Factors affecting skin elasticity
The skin is affected by both intrinsic (pathological or genetically determined) and
extrinsic (external or environmental) factors. Intrinsic factors include age, gender,
female hormones, and enzymatic breakdown of elastin or collagen while extrinsic
factors include exposure to ultraviolet light and humidity.
1.5.3.1 Intrinsic factors
With advancing age, the elastic fibres are fragmented with a more randomised
distribution of collagen fibres and an increase in cystic spaces [Balin et al. 1989]. In
addition, skin thickness has been shown to increase between the ages of 0 and 20-30
years, in both men and women, but fall thereafter [Escoffier et al. 1989]. Findings
from a study by Leveque et al. showed that skin thickness in women decreased
earlier (30-40 years) than that in men (40-50 years) [Leveque JL et al. 1980].
Genetic and endocrine factors have also been shown to affect skin elasticity [Dunn et
al. 1983]. For example, changes in female hormones during the menstrual cycle alter
skin elasticity [Berardesca E et al. 1989]. Post-menopausal women have a larger
decrease in skin elasticity, due to a significant decrease in collagen, compared to pre¬
menopausal women [Maheux et al. 1994; Sumino et al. 2004b], Hormonal
receptors, including oestrogen receptors, have been found in human skin which may
explain changes in skin during the menstrual cycle and menopause [Sator et al.
2001],
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There are a number of enzymes which degrade elastin and collagen mainly the serine
proteases, cysteine proteases, and MMPs which result in connective tissue
abnormalities [Eisner et al. 1990]. MMPs and TIMPs regulate the degradation of
collagen, elastin, and other components of the ECM [Champion et al. 1998;
Kingwell et al. 2001], MMP-1, MMP-8, MMP-13 (collagenases 1,2 and 3) are the
principal MMPs capable of initiating the degradation of fibrillar collagens I, II, III,
and V. MMP-2 and MMP-9 are important in the final degradation of fibrillar
collagens while MMP-2, MMP-3, MMP-7, MMP-9, MMP-10 and MMP-12 are
capable of degrading elastin [Lakatta 2003].
1.5.3.2 Extrinsic factors
The effect of high exposure to sunlight on skin elasticity has been widely studied.
Solar radiation varies during different seasons and causes ultraviolet erythema
(sunburn) and fragmentation and destruction of elastic tissue fibres [Serup et al.
1995]. Photodamaged skin is characterised by degraded elastic fibres and
dysregulation of elastin [Jenkins 2002], fragmentation and clumping of collagen
fibres [Fligiel et al. 2003; Varani et al. 2001], and cross-linking of collagen fibres
[Bernstein et al. 1996], The total collagen content of sun-damaged skin is 20% less
than normal exposed skin [Tzaphlidou 2004], In a study by Fisher et al., ultraviolet
light radiation was shown to increase the synthesis ofMMP, causing degeneration of
collagen fibres [Fisher et al. 1997], The effect of temperature and humidity is known
to affect the stratum corneum [Serup et al. 1995]. However, there is currently no data
on any effects temperature and humidity may have on dermal skin elasticity.
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1.6 HYPOTHESES
The following specific hypotheses will be addressed in this thesis:
Hypothesis 1
Skin elasticity is a marker of arterial stiffness, independent of age, in healthy
volunteers.
A number of techniques have been developed to assess arterial stiffness. However,
their use is limited in the clinical setting due the invasive nature of the techniques or
inaccessibility of the equipment. Non-invasive measurement of carotid-femoral
PWV is a validated technique used to assess stiffness of the arteries or their loss of
elasticity. However, carotid-femoral PWV is not a practical methodology that can be
applied very simply in a clinical setting. Therefore, this provided us with a basis for
developing a simple technique whereby an external marker of arterial stiffness can be
measured. Both the skin and arteries are made of elastin and collagen, which gives
them their characteristic elasticity. If the elasticity of the skin and arteries are found
to degrade at the same rate, there is a potential of using a non invasive measurement
of skin elasticity as a marker of arterial stiffness, especially in patients with CAD,
hypertension or diabetes.
This hypothesis was addressed by aiming to:
a) establish the reproducibility of measurements of skin elasticity in healthy
volunteers for the arm, leg and back regions of the body (Chapter 3),
69
b) evaluate the relationship between skin elasticity and arterial elasticity, independent
of age (Chapter 4).
Hypothesis 2
Arterial stiffness assessed by PWV, augmentation indices and DVP are similarly
associated with clinical risk, in patients with CAD.
A number of non-invasively derived measures are thought to represent arterial
stiffness and are potential markers of the stiffening of arteries. This provided us with
a basis to evaluate information derived from these measures in addition to that of a
known marker of arterial stiffness.
This hypothesis was addressed by aiming to determine the association between the
augmentation indices and DVP measures with PWV and clinical risk factors
(Chapter 5).
Hypothesis 3
Arterial stiffness, assessed using non-invasive techniques, is determined by
traditional cardiovascular risk factors and renalfunction, in patients with CAD.
Previous studies have shown that patients with impaired renal function who
experienced cardiovascular events have stiffer arteries [Blacher et al. 2003],
Therefore, this provided us a basis for evaluating whether arterial stiffness in patients
with CAD was related to renal function.
This hypothesis was addressed by aiming to:
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a) validate the use of the Colin® 7000, an automated tonometric device in
conjunction with the SphygmoCor® Mx Aortic Blood Pressure Monitoring System,
as an alternative device for measuring augmentation values (Chapter3).
b) evaluate the determinants of arterial stiffness, including renal function (Chapter
5).
Hypothesis 4
Endothelial dysfunction, assessed using the non-invasive technique of pressure
wave analysis, is determined by cardiovascular risk factors, in patients with CAD.
A simple non-invasive test of endothelial function has recently been developed
[Wilkinson et al. 2002b], However, this model has not been assessed to determine its
usefulness in clinical risk assessment. This provides the basis for the evaluation of
this simple non-invasive technique as a potential tool in assessing clinical risk.
This hypothesis was addressed by aiming to:
a) establish the reproducibility of changes in augmentation indices to inhaled
salbutamol, an endothelium-dependent vasodilator, as a test of endothelial function
in patients with CAD (Chapter 3),
b) determine whether endothelial function, evaluated using the technique ofPWA, is




Arterial stiffness is associated with endothelial dysfunction, in patients with CAD.
Stiffening of arteries and endothelial dysfunction has been shown to play a role in
atherosclerotic heart disease [Celermajer et al. 1992; Lovett et al. 2003]. Both
arterial stiffness and endothelial dysfunction are predictors of adverse cardiovascular
events [Gatzka et al. 1998; Suwaidi et al. 2000],
This hypothesis was addressed by aiming to assess the relationship between non¬
invasive measurements of arterial stiffness and endothelial function (Chapter 6).
Hypothesis 6
The severity ofCAD, renal function, arterial stiffness, and endothelialfunction are
prognostic indicators offatal and non-fatal outcomes, in patients with CAD.
Finally, this thesis aimed at investigating the predictors of outcomes in patients with




In order to address the aims of this research, non-invasive techniques, that have the
potential of being readily used in a clinical setting, were employed in the following
chapters. The use of non-invasive techniques allow measurements to be made easily
in a wider group of patients without the added risk of invasive procedures, for
example injury to the median nerve or the terminal artery [Tousoulis et al. 2005]
when measuring vascular function in the brachial artery. Arterial stiffness can be
assessed indirectly from measurements of the pressure and volume pulse waves.
Similarly, the non-invasive measurement of pressure waves, in combination with
systemic drug administration, provides a method of indirectly measuring endothelial
function. The use of non-invasive techniques also allows us to more easily study the
relationship between arterial stiffness and skin elasticity in healthy subjects. In this
Chapter I discuss the non-invasive techniques used in the studies presented in later
chapters.
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2.2 GENERAL STUDY REQUIREMENTS
2.2.1 Ethical considerations
All studies were undertaken in accordance with the Declaration of Helsinki from the
World Medical Association. The study protocols were approved by the local
research ethics committee and written informed consent obtained from each
participant prior to each study.
2.2.2 Study participants
All subjects abstained from alcohol for 24 hours and tobacco and caffeine-
containing drinks for at least five hours before each study. Studies were performed in
a quiet temperature controlled room maintained within the range of 22 - 25 °C and a
humidity level in the range of 40 - 50%.
2.2.3 Blood pressure measurements
Blood pressure was measured in the dominant arm using a validated [O'Brien et al.
1996] oscillometric technique (HEM-705CP, Omron Corporation, Japan) or an
integrated automated sphygmomanometer (Colin CBM-7000, Colin Medical
Technology Corporation, Japan), depending on the technique used to measure
pressure.
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2.3 ARTERIAL STIFFNESS IN PATIENTS WITH CORONARY ARTERY
DISEASE
2.3.1 Measurement of arterial stiffness
Arterial stiffness was measured using three non-invasive techniques: measurement of
pressure PWV; determination of augmentation indices from the arterial pressure
waveforms obtained by PWA and determination of the SI and RI from the arterial
volume waveforms by DVP analysis. An overview of the techniques used to measure
arterial stiffness is shown in Figure 2-1.
2.3.1.1 Pulse wave velocity
PWV is measured using an arterial tonometer. The tonometer, a piezo-resistive
pressure sensor (Millar SPT-301, Millar Instruments, Texas, USA) is connected to a
blood pressure monitoring device (SphygmoCor^ Mx, AtCor Medical, Sydney,
Australia). The tonometer flattens, but does not occlude, the artery with gentle
pressure. With flattening the circumferential pressures are equalised and a high
fidelity pressure waveform is obtained. The SphygmoCor8' system software permits
on-line recording of the waveform. PWV is determined by sequential measurements
of the pressure pulse waveform at the site ofmaximal arterial pulsation at the carotid
and femoral arteries.
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Figure 2-2 Aortic pulse wave velocity distance measurements.















Figure 2-3 Gating aortic pressure waves to the electrocardiogram.
Subfigure (a) represents the distance travelled by the pressure pulse wave and (b) and
(c) represent the calculation of the time taken for the pressure wave to travel from the






The distance (D) travelled by the pulse wave was measured over the body surface as
the direct line distance between the suprasternal notch and each of the recording sites
(Figure 2-2). The system software subtracts the distance between the carotid artery
and the suprasternal notch from that between the suprasternal notch and the femoral
artery. This final distance is an approximation to the difference in distance between
the carotid and femoral artery measurement points. The transit time was calculated
by referencing the carotid and femoral waves to the peak of the R-wave on a
simultaneously recorded electrocardiogram (ECG). The transit time is determined by
subtracting the time interval between the systolic R-wave and carotid systolic up¬
stroke from the time interval between the systolic R-wave and the femoral systolic
up-stroke. The transit time, AJPWv, is given by
ATpwv = (Tp - 7R) - (7c - 7R)
where 7> and Tc are the times of the feet of the femoral and carotid pressure waves
respectively and 7r is the time of the peak of the R-wave. The foot of a wave is
identified as the intersection of two tangents: one tangent to the last part of the
preceeding wave and the other to the upstroke of the next wave (Figure 2-3). PWV is
calculated as the difference, D, in carotid to femoral path length divided by the
transit time, A7pWv? as given by below. The influence of respiration is reduced by
averaging over one respiratory cycle which is equivalent to averaging 10 consecutive
pressure waveforms.
PWV m/s = D/ ATpwv
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2.3.1.2 Stiffness Index and Reflection Index
A non-invasive high fidelity photo-plethysmograph transducer (Micro Medical,
Gillingham, Kent, United Kingdom) using infrared light measures changes in finger
blood flow to produce a volume waveform [Mackenzie et al. 2002], It was placed on
the index finger of the left hand whilst the subject was lying supine. Temperature
controlled heating pads at the bottom and top of the sensor minimise poor quality
signals from vasoconstricted and poorly perfused subjects. Two indices are
calculated from the DVP. The first, SI, is said to be a measure of large artery
stiffness and is calculated as the subject's height, H, divided by the time, ATfivp,
between the systolic and diastolic peaks of the DVP as below (see also Figure 2-4).
SI (m/s) = H/ATdvp
The second, the RI, is a measure of reflection calculated as
RI (%) = (b/a) x 100
where a is the height of the incident wave and b is the height of the reflected wave.
The height of the reflected wave is affected by the tone of the small blood vessels.
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Figure 2-4 Digital volume pulse waveform.
Schematic of the DVP waveform in the finger from which the SI and RI are
calculated.
Time Time






Figure 2-5 Aortic pressure waveforms in elastic and stiff arteries.
Schematic of the aortic pressure waveform derived from the radial artery waveform
(a) in a person with normal arteries and (b) in a person with stiff large arteries from
which AIx is calculated.
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2.3.1.3 Augmentation Index
Systemic arterial stiffness was determined by pressure PWA. Radial artery
waveforms were analysed using a high fidelity micromanometer (SPC-301, Millar
Instruments). The radial artery is usually identified by palpation and recorded at the
level of the right wrist (at the styloid process of the radius); the arm is slightly
extended and the hand externally rotated. The probe is held still for at least 10
seconds (the time of one respiratory cycle) so that consecutive pressure waves can be
analysed. A continuously calibrated blood pressure waveform of the ascending aorta
is derived in real time from a recording of the radial artery blood pressure waveform.
Quantitative aortic data (such as systolic pressure, diastolic pressure, PP,
augmentation pressure, and ejection duration) are derived from the radial artery
waveform using the SphygmoCor® system software version 6.31 (Mx Aortic Blood
Pressure Monitoring System, AtCor Medical, Sydney, Australia). The SphygmoCor®
software uses a validated transfer function [Pauca et al. 2001] to derive AIx and
central blood pressures. AIx is calculated as the difference between the first (PI) and
second (P2) peaks, expressed as a percentage of the PP as shown in the equation
below (see also Figure 2-5).
AIx % - [(P2 -P\)/( CSBP - CDBP)] x 100
where P2 is the pressure at the 2nd peak in systole, PI is the pressure at the 1st peak
in systole, CSBP is the central systolic pressure, and CDBP is the central diastolic
pressure. The SphygmoCor® system software also calculates AIx corrected to a heart
rate of 75 beats per minute (AIx75) by reducing AIx by 4.8 for every 10 beat/minute
increase in heart rate [Wilkinson et al. 2000a; Wilkinson et al. 2002c]. The
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peripheral augmentation index (PAIx) is not provided by SphygmoCor® and so it
was calculated manually as shown below
PAIx % = [(P2 - Pl)/{ PSBP - PDBP)] x 100
where PSBP is the peripheral systolic pressure, and PDBP is the peripheral diastolic
pressure.
84
2.4 ENDOTHELIAL FUNCTION IN PATIENTS WITH CORONARY ARTERY
DISEASE
2.4.1 Measurement of endothelial function
Endothelial function was measured using an automated tonometric device containing
piezo-electric pressure sensors (Colin® 7000, Colin Medical Technology
Corporation, Japan) coupled to a SphygmoCor® system (SphygmoCor® Mx Aortic
Blood Pressure Monitoring System, AtCor Medical, Australia). This was used to
obtain continuous measurements of the pressure waveforms in the radial artery. The
Colin® has an integrated automated microphonic sphygmomanometer that measures
SBP and DBPs which are used calibrate the radial pressure pulse wave. The central
and peripheral augmentation indices were obtained as detailed in Section 2.3.1.3. A
dose of 400 /rg of salbutamol (Ventolin Evohaler®, Allen & Hanbury, Middlesex,
Uxbridge), a 132-adrenoceptor agonist, was administered to assess endothelium-
dependent vasodilation [Wilkinson et al. 2002b]. A dose of 500 /rg of glyceryl
trinitrate (Glyceryl trinitrate, Alpharma, Barnstaple, Essex, U.K.) was administered
to assess endothelium-independent vasodilatation. The technique used to measure
endothelial function is shown in Figure 2-1.
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2.5 SKIN ELASTICITY AS A MARKER OF ARTERIAL STIFFNESS
2.5.1 Techniques of measuring skin elasticity
The mechanical behaviour of skin can be assessed by either inducing a surface
deformation or by applying a load, and by assessing the resisting force of the skin or
skin deformation respectively. There are a number of available techniques that can be
used to study the mechanical properties of skin. Examples of these are torsion,
levarometry (elevation), ballistometry and suction [Eisner et al. 1990].
2.5.1.1 Torsion
Torsion involves attaching a disk on to the skin which is rotated with a pre¬
determined torque and by measuring the degree of rotation [Eisner et al. 1990]. The
torque moves the skin under the disc, without any brake from the subcutaneous
tissue, and causes the skin to elongate in a twisted fashion. Upon torque application
there is an immediate elastic deformation (Ue) followed by a creeping viscoelastic
deformation (Uv). Release of the torque is associated with an immediate recovery
(Ur). This method is most commonly used for assessing properties of the stratum
corneum.
2.5.1.2 Levarometry
Levarometry involves applying a perpendicular pull to the skin without a guard ring
[Eisner et al. 1990]. A circular piece of Perspex, about 0.5 cm in diameter, is
attached to the skin by double sided adhesive tape. The circular piece of Perspex is
connected to a counterbalanced measuring rod which has a net pressure of less than
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lg/cm . Elevating weights used vary between 5 to 40 g/cm . This method is used as a
measure of the slackness of skin.
2.5.1.3 Ballistometry
Ballistometry is a technique which involves the use of a small stylus or impacting
mass that strikes the skin at a low force and measuring the indentation and resilience
of the skin. When the stylus strikes the skin surface the elastic component of the skin
begins to restore some of the kinetic energy of the falling object. Subsequent release
of this kinetic energy by the skin provides the rebound. The ground substance in skin
slows compression and rebound and the largest rebound is found with the largest
ratio of the elastic to viscous component.
2.5.1.4 Suction
The technique of suction involves a small dome of skin being sucked
into a measurement cup, attached to a probe, by a known vacuum and the
displacement of the skin is measured. The skin around the opening of the probe is
kept in position by an external guard ring attached to the probe. The depth of skin
penetration is measured by an optical system. During application of a vacuum force
there is an initial fast phase determined by the elastic component, followed by a
viscoelastic phase and finally a viscous phase. When the vacuum force is released to
0 mbar of negative pressure, there is a fast initial drop in the elastic phase, followed
by the viscoelastic and the plastic component.
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2.5.2 Methodology used to measure skin elasticity in this research
Skin elasticity was measured in this thesis using a non-invasive suction device
(Cutometer® MPA 580, Courage and Khazaka, Koln, Germany) with a hand held
probe linked to a computer. The Cutometer® consists of a micro-processor, an air
evacuation system and a probe with an 8 mm diameter suction cup [Courage et al.
2003]. The probe is applied perpendicular to the skin surface and measures the
vertical deformation of the skin as a function of time [Dobrev 2002], A constant
controlled vacuum force of 450 mbar is applied for 5 seconds after which the probe's
vacuum is reduced to 0 mbar for 3 seconds allowing the skin to return to its original
position. A probe with a small aperture, e.g. 2 mm in diameter, causes a
disproportionate deformation of the skin whereby only the epidermis and outer
dermis can unfold and undergo strain. Therefore, a larger aperture i.e. 8 mm in
diameter, was chosen for the full thickness of the skin to deform [Dobrev 2002], The
system software calculates a number of absolute and relative parameters from the
waveform of skin deformation with time. The absolute parameters are dependent on
skin thickness. However, the ratios of the absolute parameters (relative parameters)
are independent of skin thickness and were, therefore, used for analysis. Elasticity
measurements were made at the following five regions: the back, above the right
shoulder blade; the dorsal and ventral forearm, midway between the elbow and the
wrist; the anterior half of the upper arm, midway between the shoulder and the
elbow; and, the anterior third of the upper leg, midway between the groin and the
knee. An overview of the techniques used to measure skin elasticity and arterial
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2.6 OUTCOMES
Follow-up time was calculated as days between the first study visit and date of the first
cardiovascular event or date of last follow-up for censored subjects. Due to the initial
short follow-up up to July 2005 only a small number of deaths were expected.
Therefore, the primary pre-defined outcome of this study was a composite end-point
[Anavekar et al. 2004; Beddhu et al. 2002; Santopinto et al. 2003] consisting of death,
AMI, stroke and hospitalisation due to CHD while the post-hoc outcome studied was
future coronary intervention (CABG or PTCA).
Follow-up data for hospitalisations due to an AMI, CHD admission, stroke, and
coronary intervention came from the Scottish Morbidity Record for all inpatient and
daycase discharges (SMR 01). Individual diagnoses were classified according to the 10th
International Classification of Disease 10th revision (ICD-10) codes.The codes for CHD
are 120-125; AMI, 121-122; angina, 120 and 1249; cardiac failure, 150; cerebrovascular
disease, 160-169 and G45; and stroke, 161-164. CHD admissions were defined as
admissions relating to cardiovascular death, non-fatal MI, recurrent hospitalisation for
myocardial ischaemia, revascularisation procedures or hospitalised angina.
Operations codes used were based on Office for Populations Census and Surveys
Version 4th Revision Classification of Surgical Operations and Procedures (OPCS4)
codes. The codes for CABG were K40-K46; angioplasty, K49 and K50.1; and
angiography, K63 and K65. Revascularisation procedures 6 months after study
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participation were included in the analysis while revascularisation procedures during this
period were assumed to be planned elective procedures.
Deceased subjects were confirmed by death certificates from the General Register Office
and all other subjects were considered to be alive at the end of the follow-up period.
Cardiovascular death was defined as fatal MI or sudden death in the presence of CHD
and the absence of other life threatening disease.
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2.7 BIOCHEMICAL BLOOD ANALYSIS
Venous blood was obtained on the day of the study and collected into an EDTA tube
(Monovette®, Sarstedt, Numbrecht, Germany). Clinical biochemistry analyses were
performed by the regional clinical laboratories. The Vitros® 950 Chemistry Products
system (Ortho-Clinical Diagnostics Inc., Rochester, New York) was used for analysis of
serum concentrations of total cholesterol, high density lipoproteins cholesterol (HDL-C),
triglycerides (TG) and serum creatinine. Due to differing methods of measuring serum
creatinine concentrations between the Royal Infirmary and Western General Hospital
there is a potential for a bias. However as this bias is only significant for high serum
creatinine concentrations and the majority of subjects with CAD had normal serum
creatinine concentrations the differences in measurements of serum creatinine
concentration are not expected to confound results.
2.7.1 Total cholesterol concentration
Total cholesterol was analysed using the Vitros& CHOL slide based on an enzymatic
method similar to that of Allain et al. at 37°C [Allain et al. 1920]. A 10 /xL drop of
patient sample is placed on the slide which contains the Tritron X-100 surfactant. This
surfactant aids the disassociation of the cholesterol and cholesterol esters from the
lipoprotein complexes. The hydrolysis of the cholesterol esters to cholesterol is
catalysed by cholesterol ester hydrolase. The next step involves the oxidation of free
cholesterol by cholesterol oxidase to form cholestenone and hydrogen peroxide. A leuco
dye is oxidised by hydrogen peroxide with the help of peroxidase to form a coloured
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dye. The density of this coloured dye is proportional to the cholesterol concentration in
the sample and is measured by reflectance spectrophotometry. The lower limit of
sensitivity for this test following the NCCLS Protocol EP5-T2 [Wayne 1992] is 1.29
mmol/L. The within day variability (SD) for a mean concentration of 3.9 mmol/L is 0.07
and for a mean concentration of 6.4 mmol/L is 0.13. The correlation coefficient for the
accuracy of this test following the NCCLS Protocol EP9-A [Wayne 1995] in
comparison to that of Abell-Kendall is 1.0 [Abell et al. 1952],
2.7.2 Triglyceride concentration
Triglyceride concentration was analysed using the Vitros® TRIG slide based on an
enzymatic method described by Spayd at al [Spayd et al. 1978]. A drop of the patient's
blood sample is placed on the slide containing Triton X-100 which aids the
disassociation of TG from the lipoprotein complexes. The triglyceride molecules are
hydrolysed by lipase and give rise to glycerol and fatty acids. Glycerol is phosphyrylated
by glycerol kinase with the aid of adenosine triphosphate. This is followed by the
oxidation of L-a-glycerophosphate to dihydroxyacetone phosphate and hydrogen
peroxide by the aid of L-a-glycerol phosphate oxidase. Finally, a leuco dye is oxidised
by hydrogen peroxide in the presence of a peroxidase catalyst. The density of the dye
formed is proportional to the triglyceride concentration and is measured by reflectance
spectrophotometry. The lower limit sensitivity of this test is 0.11 mmol/L. The within-
day variability (SD) for a mean concentration of 1.24 mmol/L was 0.01 and for a
concentration of 2.62 mmol/L was 0.02 based on the NCCLS Protocol EP5 [Wayne
1999]. This correlation coefficient of this test has an accuracy of 0.99 using the NCCLS
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Protocol EP9 [Wayne 1995] when analysed against a method of Fossati and Prencipe
[Fossati et al. 1982].
2.7.3 High density lipoprotein cholesterol
The patients sample is pre-treated with Vitros® Magnetic HDF-Cholesterol reagent and
the HDF cholesterol is measured by the Vitros CHOF slide. FDL and very low-density
lipoprotein (VLDL) are precipitated by dextran sulphate and magnesium chloride
allowing HDF to separate out. A magnetic field is applied to remove the precipitated
lipoproteins from the supernate containing HDL. Approximately 10/xL of the pre-treated
patients sample is placed on the slide and reacts to produce hydrogen peroxide. The
hydrogen peroxide reacts with the leuco dye to produce a blue dye complex from which
the amount of reflectance is calculated. The lower limit sensitivity for this test is 0.08
mmol/L. The within-day variability (SD) for a mean concentration of 0.81 mmol/L is
0.019 and for a concentration of 1.35 mmol/L is 0.047 based on the NCCLS Protocol
EP5-T2 [Wayne 1992]. The correlation coefficient for the accuracy of this test is 1.00 in
Or)
comparison to the Vitros HDL cholesterol (Individual Tube) method.
2.7.4 Serum creatinine concentrations
A drop of the patients sample is placed on the Vitros® CREA slide. Creatinine is
hydrolysed by the reagent and is converted to sarcosine and urea by creatinine
aminohydrolase. In the presence of sarcosine oxidase, sarcosine is oxidised to glycine
formaldehyde and hydrogen peroxide. This is followed by the oxidation of the leuco dye
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by a peroxide catalyst to produce a coloured product. After the addition of the patient's
sample, the slide is incubated. Endogenous creatinine in the sample is oxidised during
the initial reaction phase and the resulting change in reflection density is measured. The
concentration of creatinine present in the sample is proportional to the rate of change in
reflection density. This test can detect serum concentration ranges between 4 - 1238
/xmol/L. The with-in day variability (SD) for a mean concentration 81 /xmol/L is 0.7 and
for a mean concentration of 499 /xmol/L is 4.1. The correlation coefficient for the
accuracy of this test is 0.99 in comparison to analysis by High Performance Liquid
Chromatography [Ambrose et al. 1983].
2.7.5 Low DENSITY LIPOPROTEIN CHOLESTEROL
Low density lipoprotein cholesterol (LDL-C) concentration was calculated by the
Lriedewald equation [Lriedewald et al. 1972]
ClDL (mg/dL) = Cpiasma- Chdl - TG/5
where, Cldl denotes LDL-C concentration; CpiaSma, total cholesterol concentration; Chdl,
HDL-C concentration; and TG the triglyceride concentration.
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2.8 DATA ANALYSIS
Statistical analysis was performed using Microsoft Excel 2002 and SPSS version 11.5
for Windows program (SPSS, Inc., Chicago, IL, USA). All results are expressed as mean
± standard deviation (SD). Data were examined by two tailed Student's t-test, analysis of
variance (ANOVA), analysis of covariance (ANCOVA) and regression analysis where
appropriate. The Bonferroni correction was used for all post-hoc comparisons calculated
as a - 0.05/k (a is the alpha value for each comparison and k is the number of
comparisons carried out). Stepwise linear regression was used for multivariate analysis.
Cumulative survival and event free probabilities were determined using the Kaplan-
Meier product-limit method and compared by the Mantel (log-rank) test. All testing was
two-sided and significance was taken at the 5% level.
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CHAPTER 3: DEVELOPMENT OF METHODOLOGY
This chapter discusses the reproducibility of two techniques employed in the following
chapters. First, the reproducibility ofmeasurements of skin elasticity in different regions
of the body was assessed. This study was carried out to determine which skin elasticity
ratios and which skin regions were most reproducible. Second, I aimed to assess the
reproducibility changes in augmentation indices following the administration of inhaled
salbutamol as a non-invasive test of endothelial function. This chapter is also aimed at
(R) • •
validating the use of an automated sphygmomanometer, Colm 7000, m comparison to a
more commonly used tonometric device, the Millar micromanometer.
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3.1 REPRODUCIBILITY OF MEASUREMENTS OF SKIN ELASTICITY
3.1.1 Introduction
The Cutometer" MPA 580, as discussed in Chapter 1, is an appropriate tool for
measuring skin elasticity in our group of subjects. This is because the Cutometer® allows
the determination of dermal skin elasticity with a larger probe and it is a simple
technique that can be readily used in a clinical setting. The reproducibility from this
device has not previously been studied. Therefore, this study was undertaken to evaluate
the reproducibility of the skin elasticity ratios R2 (Ua/Uf), R5 (Ur/Ue), R6 (Uv/Ue) and
R7 (Ur/Uf) for the dorsal, ventral and upper arm as well as the upper leg and back
[Serupeta/. 1995].
Elasticity of the skin and arteries is structurally determined by elastin and collagen in the
dermal and medial layers respectively. Change in elasticity of the arteries has been
found in patients with connective tissue disorders such as Ehlers-Danlos syndrome type
IV, PXE, and Marfans syndrome. Patients with Ehlers-Danlos syndrome have reduced
collagen content in the skin and aorta and, more specifically, they lack type HI collagen
[Pope et al. 1975]. Reduced collagen content in patients results in fragile and
hyperextensible connective tissues and patients are, therefore, more prone to rupturing of
the arteries. Patients with PXE, on the other hand, have fragmented elastic fibres and
accumulations of calcium and proteoglycans in the skin and also in their carotid arteries





Healthy volunteers were recruited through advertisements at the local churches and at
the Western General Hospital, in Edinburgh. Ten healthy volunteers attended on 2
occasions 5 days apart. The exclusion criteria were that subjects could not be on: any
long term medications, corticosteroids or recent antibiotic therapy. Also, subjects were
excluded if they had a skin disorder or had recent exposure to high levels of ultraviolet
(UV) light.
3.1.2.2 Measurements
Subjects were asked not to use cosmetics, moisturisers or moisturising baths on the day
of the study. Skin elasticity was measured on the back, arm, and leg using a non¬
invasive suction device with a hand held probe linked to the Cutometer® MPA 580
(Courage and Khazaka, Koln, Germany). This system consists of a micro-processor and
an air evacuation system with an 8mm diameter suction cup probe. The measuring
probe is held in position by an adhesive guard ring to reduce lateral displacement of the
skin as much as possible.
Elasticity measurements on the back were made above the right shoulder blade. Three
measurements were made on the arm: two were made on the dorsal and ventral aspect of
the right forearm, midway between the elbow and the wrist; and one was made on the
inner side of the upper arm, midway between the shoulder and the elbow. Measurements
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of the leg were made on the upper anterior third of the leg between the knee and the
groin.
3.1.2.3 Study Protocol
Subjects were rested for 10 minutes and then measurements of skin elasticity were taken
in the following order: dorsal arm, ventral arm, upper arm, upper leg and back (
Figure 3-1). Each set of measurements consisted of 10 cycles, each cycle of which
comprised the skin being suctioned for 5 seconds and released for 3 seconds. These sets
of measurements were only made once to avoid the phenomenon of creep which is an
increase in deformation of the skin as a function of time when a constant stress is
applied.
3.1.2.4 Data Analysis
Statistical analysis was performed using Microsoft Excel 2002. The R2, R5, R6, and R7
ratios of skin elasticity measurements were examined by Bland-Altman plots and two
tailed Student's paired t-test. All results are expressed as mean ± SD. Statistical
significance was taken at the 5% level.
101
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Figure 3-1 Study protocol for the reproducibility of skin elasticity measurements.
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3.1.3 Results
The study group comprised of 8 women and 2 men with a mean age of 33 ± 8 years
(range 28 - 52). Subjects attended a second visit after a mean time of 5 ± 1 days (range
4-6 days). Table 3-1 shows the four mean skin elasticity ratios taken at the five body
regions for the first and second visits. Bland-Altman plots for the reproducibility in
measurements of R2, R5, R6 and R7 for the various body regions are shown in Figures
3.2 - 3.6. The data shown in the table and figures is summarised in the following
sections.
3.1.3.1 Back
The R6 skin elasticity ratio had the least difference, with one outlying subject. This was
followed by the R5 and R7 ratios, after the R2 ratio, as having the largest difference
between visits. The mean difference in R5, R6 and R7 was increased by one extreme
outlying subject (Figure 3-2).
3.1.3.2 Dorsal arm
The R6 ratio had the least mean difference and the least variability in measurements,
except for one extreme outlying subject. Measures of R7 had the least mean differences
and both the R2 and R5 values very highly variable (Figure 3-3).
3.1.3.3 Ventral arm
The R2 and R7 measures had the least differences between visits. However, the R6
values were the most closely distributed, except for 1 extreme outlier. Measures of R5
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were also closely distributed except for one slightly outlying subject and an extreme
outlier (Figure 3-4)
3.1.3.4 Upper Arm
The R6 ratio was the most reproducible with the least mean difference between visits,
followed by the R5 and R7 measures. The R2, R6 and R7 were affected by one extreme
outlying subject which, if excluded, would have reduced the mean differences and
improved the reproducibility of these parameters (Figure 3-5).
3.1.3.5 Upper Leg
The R6 parameter had the least mean difference between visits. However, the R2
parameters were the least variable, with one outlying subject. Measurements of R2 were
close to the zero line. However, there were two outliers that increased the mean
difference. The R7 measurement showed most variability. One outlying subject
contributed to the increase in the mean difference for both R5 and R7 ratios (Figure 3-6).
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3.1.4 Discussion
The R2, R5, R6 and R7 parameters were most reproducible in the upper arm and
upper leg. Measurements in the upper arm had the least scatter while those of the
upper leg had the least mean difference between measurements. Of the four ratios the
R6 was the ratio most consistently reproducible for the different body regions.
The mean differences of the four ratios were increased by an outlying point for most
of the measurements. Outlying points were found to be from different female
subjects. With over two-thirds of the subjects studied being females, there is
potential for changes in hormones to confound skin elasticity measurements.
Oestrogen and other hormonal receptors have been noted to be present in human skin
[Sumino et al. 2004a]. In addition, hormone replacement therapy has been shown to
improve or maintain the skin's thickness, collagen content and elastic properties
[Dunn et al. 1997; Sator et al. 2001]. The possible confounding effects of hormonal
changes during the ovulation period was reduced by studying female subjects
between days 7-28 of their menstrual cycle [Berardesca E et al. 1989].
Of the five regions of the body the measurement from the back showed the largest
differences between visits and varied most. This can be attributed to the difficulty in
taking measurements due to the movement of the body with respiration.
Measurements of the dorsal arm were taken as a comparison to the ventral arm which
is less exposed to the effects of ultraviolet radiation, but neither were found to be as
reproducible as those from the upper arm and leg. Measurements from the ventral
arm were difficult to record due to the presence of underlying veins which made it
difficult to replicate the measurements during the second visit. In contrast,
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measurements from the upper arm and leg were the most reproducible as these areas
are least affected by extrinsic factors.
There are other factors that may play a role in the variability between skin
measurements. One example is skin hydration which increases the elasticity of the
skin. The skin's ability to acclimatise to the temperature and humidity levels of the
study room may have varied between the two visits and may have, therefore, led to
some differences in measurements. In a previous study [Sator et al. 2001],
menopausal female subjects were required to rest for two hours under standard room
conditions to allow them to adapt to the temperature and humidity levels. Subjects in
our study rested for at least 20 minutes, which may not have been sufficiently long
for their skin to adapt. However, if this technique is intended for use in a clinical
setting, it would be impractical for patients to be rested for such a long duration.
3.1.4.1 Study limitations
The main limitation of this study is the relatively small number of subjects in the
older age group. Second, this study had a narrow age distribution of subjects which
limited our understanding of the reproducibility of the skin elasticity measurement
technique in older people. Third, the majority of subjects studied were women, which
makes it difficult to determine whether men have more reproducible measurements




We conclude that the upper arm and upper leg were the regions of the skin that were
most reproducible in this study while the R6 parameter was the most reproducible
skin elasticity ratio.
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3.2 VALIDATION OF THE USE OF THE COLIN® 7000 IN PATIENTS WITH
CORONARY ARTERY DISEASE
3.2.1 Introduction
The non-invasive technique of arterial tonometry is increasingly being chosen as a
method ofmeasuring arterial pressure waves. The micromanometer is connected to a
system software such as SphygmoCor® which derives central aortic pressure
waveforms from peripheral arterial pressure waves using a transfer function
[Karamanoglu et al. 1993; Pauca et al. 2001]. Central blood pressures and various
arterial indices are than calculated from the central pressure waveforms. The
micromanometer most commonly used with SphygmoCor® is the Millar
micromanometer [McLeod et al. 2004; Weber et al. 2004; Wilkinson et al. 2002c;
Wilkinson et al. 2002b], Continous measurements carried out using this
micromanometer, however, depend on the accuracy with which the operator replaces
the micromanometer probe at the same site after each consecutive measurement. An
alternative device that can be used in conjunction with the SphygmoCor" system is
the Colin8, 7000. It is composed of an array of tonometers and has been designed in
the form of a wrist band which is applied to the radial artery. The Colin®
automatically detects the strongest point of the radial pulse for pressure wave
recordings and is able to carry out measurements at predefined time intervals. The
Millar micromanometer, in comparison, is more operator-dependent and is adversely
affected by the placement of the probe at different angles to the radial artery during
consecutive measurements. This study was aimed at validating the use of the Colin5,
against the more commonly used Millar tonometer in patients with CAD, for which
there is no data to date. If the measurements recorded using the Colin are in
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agreement with those from the Millar micromanometer, the Colin® would be a better
alternative to use in studies that record large numbers of continuous measurements.
3.2.2 Methods
3.2.2.1 Study Subjects
Patients with CAD who took part in the endothelial function study (discussed in
Chapter 6) were invited to take part in this study. The first fifteen subjects who
agreed comprised the population for this study. Approval for all studies was obtained
from the local research ethics committee and informed written consent obtained from
each participant prior to the study.
3.2.2.2 Measurements
Subjects were studied at least 2 hours after their morning medications and were
asked to avoid caffeine and food 2 hours prior to the study. PWA was carried out
using the SphygmoCor® system (SphygmoCor® Mx, AtCor Medical, Sydney,
Australia, version 6.31). This system uses the technique of applanation tonometry, in
which a high-fidelity micromanometer (SPT-301, Millar Instruments, Texas, USA)
or a probe containing piezoelectric pressure sensors (Colin5 7000, Colin Medical
Technology Corporation, Japan) is used to determine AIx and AIx75. Brachial blood
pressure was measured using a validated oscillometric technique (HEM-705CP;
Omron Corporation, Japan) in combination with the micromanometer or an
automated blood pressure monitor which is incorporated into the Colin.
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3.2.2.3 Study Protocol
The study protocol is detailed in Figure 3-7. This protocol consisted of the following
sequence ofmeasurements:
a blood pressure measurement followed by the mean of 3 augmentation
measurements using the Millar micromanometer,
a blood pressure measurement followed by the mean of 3 augmentation
measurements using the Colin®,
a blood pressure measurement, followed by the mean of 3 augmentation
measurements using the Colin®,
a blood pressure measurement, followed by the mean of 3 augmentation
measurements using the Millar micromanometer,
3.2.2.4 Data Analysis
Statistical analysis was performed using Microsoft Excel 2002 and SPSS version
11.5 for Windows program (SPSS, Inc., Chicago, IL, USA). Data were examined by
Bland-Altman plots and two tailed Student's t-test. All results are expressed as mean
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3.2.3 Results
The group of subjects who took part in the validation study comprised 7 males and 8
females with a mean age of 65 ± 6.7 years. Mean central blood pressure was 124/70
± 15/12, and mean peripheral blood pressure was 116/71 ± 16/12.
Nine subjects were in CCS Class 1, while 5 subjects were in CCS Class 2, and 1
subject in CCS Class 3. Out of the 15 subjects, 1 had no coronary vessel disease, 6
had disease in 1 coronary vessel, 3 had 2-vessel disease and 5 patients had 3-vessel
disease. The drug and medical history of all subjects is outlined in Table 3-2.
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Ischaemic heart disease 93.3 (14)






ACE inhibitors 26.7 (4)
Calcium channel blockers 33.3 (5)
Angiotensin receptor blocker 6.7(1)
Nicorandil 33.3 (5)
Statin 86.7(13)
Values are proportions. N=15
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The mean baseline values, SDs and mean differences are shown in Table 3-3 There
were no significant differences in the mean values of AIx and AIx75 between the
first and second sets of recordings carried out using a micromanometer. Similarly,
there were no differences between sets of recordings made using the Colin'8'. There
were also no significant differences in the mean values or SDs of AIx or AIx75
between the micromanometer and Colin®.
There was a strong positive correlation in AIx (r = 0.87, P < 0.001) and AIx75 (r =
0.79, P < 0.001) on assessment of scatter plots of measurements from the
micromanometer and the Colin® (Figure 3-8). The Bland-Altman plots for the
reproducibility in measurements of AIx and AIx75 are shown in Figure 3-9. The
mean of the differences for AIx and AIx75 was -0.2 ± 4.6% and -0.3 ± 4.9%
respectively.
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The augmentation values of the micromanometer were strongly correlated with those
of the Colin®. There were no significant differences between these techniques, nor
were there differences between repeated measurements of the individual techniques.
The strong correlation between the augmentation values measured using the Millar
micromanometer and Colin® devices indicate that the Colin® can be used as an
alternative device to the micromanometer. This conclusion is reinforced by our
failure to find any significant differences in augmentation values measured for each
device. The sequence of measurements (micromanometer, Colin*, Colin®,
micromanometer) strengthens these findings by reducing any possible errors due to
changes in blood pressure. Therefore, any variations in augmentation values are more
likely to be caused by the variability in measures caused by the individual devices.
However, the differences in augmentation values between devices were no greater
than differences in the reproducibility of AIx, carried out using a micromanometer,
in a study by Wilkinson et al. [Wilkinson et al. 1998], In the latter study, the mean
difference in AIx from a single device (Millar micromanometer) was 0.49 ± 5.4%.
Therefore, there is no greater variability between measurements from these 2 devices
as compared to measurements from a single device.
3.2.4.1 Limitations
This study was limited to a small number of subjects, nevertheless, there was a good
agreement in augmentation values between the Millarmicromanometer and Colin®.
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3.2.5 Conclusions
The augmentation values derived using measurements from the Colin® are in good
agreement with those of the micromanometer.
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3.3 REPRODUCIBILITY OF THE SALBUTAMOL RESPONSE AS A TEST OF
ENDOTHELIUM-DEPENDENT FUNCTON IN PATIENTS WITH
CORONARY ARTERY DISEASE
3.3.1 Introduction
Endothelial dysfunction has been shown to predict cardiovascular events in patients
with CAD [Schachinger et al. 2000] as well as in patients with angiographically
normal coronary arteries [Halcox et al. 2002b]. Impairment of endothelial function,
as measured by flow-mediated dilatation (FMD), predicts events in patients with
chest pain while a normal FMD in the brachial artery is associated with a low risk of
cardiac events [Neunteufl et al. 2000].
A number of techniques have been used to study endothelial function in the coronary
and peripheral vascular bed. The most reliable method for detection of endothelial
dysfunction involves determining the change in coronary blood flow, coronary artery
diameter, and coronary vascular resistance to intracoronary infusion of acetylcholine
[Deanfield et al. 2005]. It is, however, expensive and has risks related to the
procedure of angiography which makes it an unsuitable screening tool for the general
population. An alternative reliable and reproducible technique is intrabrachial
infusion of vasoactive substances during venous occlusion strain-gauge
plethysmography. One of the drawbacks of using this technique is it is an invasive
and time consuming technique that does not lend itself to large patient populations
[Widlansky et al. 2003].
Attempts to overcome some of the problems faced by the above techniques have led
to development of non-invasive techniques. Examples include high resolution
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ultrasound to determine FMD and strain-gauge venous plethysmography during
reactive hyperaemia. FMD of the brachial artery is a validated technique [Deanfield
et al. 2005] and is well correlated with coronary endothelial vasodilator function
[Anderson et al. 1995b], However, investigators need to be trained in assessing FMD
results compared to strain gauge venous plethysmography which is less observer
dependent [Tousoulis et al. 2005],
The technique of PWA with the administration of GTN and salbutamol as a test of
endothelial function is a relatively new non-invasive technique. The reflected arterial
pressure wave, influenced by the resistance of peripheral vessel tone, is altered by
GTN and salbutamol. GTN, an endothelium-independent vasodilator, is an
exogenous source of NO while salbutamol, an endothelium-dependent vasodilator,
generates NO through its action on the endothelium. Both GTN and salbutamol result
in a reduction in stiffness via NO dependent pathways and can be used to assess
endothelial function.
The GTN and salbutamol responses have been described in hypercholesterolaemics
[Wilkinson et al. 2002b], CAD [Hayward et al. 2002] and patients with diabetes
[Chowienczyk et al. 1999] and has been validated as a model of endothelial
dysfunction through nitric oxide synthase inhibition [Chowienczyk et al. 1999;
Dawes et al. 1997], There are currently limited data on the reproducibility of this
model with only one study [Hayward et al. 2002] to date carried out in healthy





Subjects who had taken part in a large study looking at endothelial function in
patients with CAD at the Western General Hospital, discussed in Chapter 6, were
invited to take part in this study. The first twenty subjects who agreed to attend a
second visit a week later comprised the reproducibility study population.
3.3.2.2 Measurements
Subjects had all vasoactive medications withheld on the morning of the study and
were studied after an overnight fast on both occasions. Brachial blood pressure was
measured using a validated oscillometric technique (HEM-705CP; Omron
Corporation, Japan). Peripheral pressure pulse waveforms were determined by a
sensor containing piezoelectric pressure transducers (Colin® 7000; Colin Medical
Technology Corporation, Japan) from which the central waveform was derived. AIx
and AIx75 were calculated using the SphygmoCor® system software.
3.3.2.3 Study Protocol
The study protocol is detailed in Figure 3-10. Subjects underwent arterial stiffness
and vascular function measurements during their first visit. During their second visit
subjects repeated only the test of endothelial function which comprised
measurements of augmentation indices in response to salbutamol.
3.3.2.4 Data Analysis
Statistical analysis was performed using Microsoft Excel 2002 and SPSS version
11.5 for Windows program (SPSS, Inc., Chicago, IL, USA). Salbutamol responses
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were determined by calculating peak changes and AUCs. Data were examined by
Bland-Altman plots and two tailed Student's t-test. All results are expressed as mean













^403o2AO[1356 Time(min)—» Visit2: Endothelialfunctionprot co <i Rest 1minimi1111 -20-1001023 Time(min)—» administrationof500/xgGTN administrationof400/xgsalbutam l Figure3-10Protocolfsalbutamoreproducibilitytudy. Schematicoft estudyprotocolundertaken.Tdow w ra r ws,A,eno strecordingimfmeasurement. 130
3.3.3 Results
The twenty subjects who took part in the reproducibility study comprised 18 men and
2 women with a mean age of 61.7 ± 7.7 years. Mean central blood pressure was
125/76 ± 16/10, and mean peripheral blood pressure was 132/75 ± 16/10. Patients
returned for a second visit after a mean time of 8 ± 2 days. Fifteen patients comprised
the Canadian Cardiovascular Society Angina classification (CCS) Class 1, while 4
patients were in CCS Class 2, and 1 patient in CCS Class 3. Out of the 20 patients, 6
had disease in 1 coronary vessel, 8 had 2-vessel disease and 6 patients had 3-vessel
disease. The drug and medical history of all subjects is outlined in Table 3-4.
The mean baseline values, peak changes and area under the curves for responses to
salbutamol are shown in Table 3-5. The Bland-Altman plots for the reproducibility in
measurements of AIx and AIx75 are shown below in Figure 3-11. The mean of
differences in peak responses for AIx and AIx75 was 0.02 ± 6.6% and 0.37 ± 6.4%
respectively. No significant differences were found between visits (P < 0.49; P <
0.40). The time to peak effect of salbutamol was earlier in the first visit compared to
that of the second visit. The mean difference in AUC between visits were 37 ± 198
and 40 ± 184 for AIx and AIx75 with no significant differences between visits (P <
0.21; P < 0.17) respectively.
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3.3.4 Discussion
The peak effect of the salbutamol response was well reproduced during the second visit.
The AUC of salbutamol, however, was not as well reproduced mainly due to the
variability in responses between the 2 visits for three subjects.
The mean difference in peak response was 0.02 ± 6.6 for AIx and 0.37 ± 6.4 for AIx75.
The mean difference in our study was lower than that previously reported by Wilkinson
et al. [Wilkinson et al. 2002b] who found the mean difference in peak AIx to be -2.3 ±
3.0% in 13 healthy subjects. Prior to their study in 2002, Wilkinson et al. [Wilkinson et
al. 1998] carried out a study of 33 subjects (5 controls, 12 diabetics and 16
hypertensives) in which 2 measurements of AIx were made. They found the mean
difference to be 0.49 ± 5.37%. Wilkinson's measurements of baseline AIx% were
carried out sequentially on the same day. The mean baseline difference was slightly
larger in our study population. However, the SDs were slightly smaller compared to
those found by Wilkinson. This implies that the amount of variability found in baseline
measurements ofAIx and AIx75 are comparable to that found during the peak change in
AIx and AIx75 to salbutamol. The mean difference in the AUC was large and patients
were found to have a larger overall response to salbutamol during the second visit
compared to the first. The large SDs, in our study, were mainly due to the measurements
from three outlying patients. They may be attributed to the use of PWA with the
administration of GTN and salbutamol being a poor technique or alternatively due to
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polymorphisms of the human 62 adrenoreceptor resulting in variability of augmentation
measures not determined by endothelial function [Green et al. 1994; Reihsaus et al.
1993],
An increasing heart rate results in the reflected wave arriving during diastole, while a
reduced heart rate would have led to the reflected wave arriving during the systolic
phase [Davies et al. 2003], In order to correct for the effect of heart rate on the
variability of the data, changes in AIx corrected to a heart rate of 75 beats per minute
were made. The peak changes in AIx75 had less variability than the peak change in
AIx. However, correction for heart rate did not differentiate the AUC responses in AIx
and AIx75. This may be partly due to the cumulative variability of the different time
points when calculating AUCs for each subject confounding corrections of heart rate.
In the study by Wilkinson et al. [Wilkinson et al. 2002b], the peak change in AIx in 13
healthy subjects was -9.3 ±3.8 (1st visit) and —11.6 ± 3.8 (2nd visit), while patients in our
reproducibility study who had CAD were found to have a peak change in AIx of-7.7 ±
6.5 (1st visit) and -7.7 ± 4.4 (2nd visit). The minimum mean difference, based on the
second visit of these 2 studies, required to detect endothelial dysfunction in patients with
CAD is about 4%. Therefore based on these data, a power calculation indicates that a
sample size of 85 subjects is required for an 80% power to detect a 4% difference in the
peak responses to salbutamol.
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3.3.4.1 Limitations
A number of limitations are evident in this study, and these are as follows. First, subjects
only undertook the endothelial function test protocol during their second visit. This may
have led to a hangover effect of GTN on the salbutamol response during the first visit
and therefore larger peak, as evidenced by the larger SDs, and the AUCs in
augmentation indices in response to salbutamol. However, in a study by Greig et al.
[Greig et al. 2005] the response to GTN persisted up to 25 minutes therefore eliminating
the likelihood of a hangover effect of GTN in our subjects after 30 minutes. Second,
patients may be better at their inhaler technique on their second visit and this "training
effect" may explain the reduced variability in responses during the second visit. Third,
the peak effect of salbutamol was expected to occur roughly around 11 minutes based on
data from Wilkinson et al. [Wilkinson et al. 2002b] who found the mean peak
salbutamol response to occur at 11 ± 3 minutes in normocholesterolemics and 12 ± 3
minutes in hypercholesterolaemics. Measurements were recorded every minute for the
first 11 minutes followed by measurements every 5 minutes for a period of 30 minutes.
The result from our group of subjects with CAD indicates that the mean peak response
to salbutamol took place at 13 ± 8 minutes for both AIx and AIx75. Therefore, there is
the potential of underestimating peak effects which take place in between the 5-minute
intervals. In addition the time to peak effect may have been underestimated were they to
fall in between the 5 minute intervals. If these limitations had been avoided the precision
of the endothelial response during both visits would have been better.
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3.3.5 Conclusions
The Bland-Altman plots reflect that, on the whole, the daily variability was low, but
there were a number of patients who had highly variable readings during the two visits
which could adversely affect the interpretation of their response to salbutamol in a
clinical setting. Variabilty in endothelial function measures may be due to the
endothelial function test being a poor technique or human B2-adrenoreceptor
polymorphisms.
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CHAPTER 4: SKIN ELASTICITY AS A MARKER OF ARTERIAL ELASTICITY IN
HEALTHY VOLUNTEERS
4.1 INTRODUCTION
Both arterial wall elasticity and skin elasticity are determined by their constituents
elastin and collagen [Loscalzo et al. 1996; Tzaphlidou 2004]. We are led to believe that
there is a relationship between skin elasticity and arterial elasticity by the observation
that an increase in both arterial and skin elasticity has been found in certain hereditary
disorders such as Ehlers-Danlos syndrome, Marfan syndrome and PXE [Gogly et al.
1998; Kornet et al. 2004; Pope et al. 1975] as well as in patients with intracranial
aneurysms [Grond-Ginsbach et al. 2002] and cervical artery dissections [Brandt et al.
2001], In contrast, a decrease in arterial and skin elasticity has been found in women
with a history ofpre-eclampsia [Elvan-Taspnar et al. 2005].
At this point it is instructive to consider the underlying pathological changes that cause
arterial stiffness. In stiff arteries there is increased abnormal collagen, frayed and broken
elastin molecules, abnormal or disarrayed endothelial cells, and infiltration of
macrophages, mononuclear cells and vascular smooth muscle cells [Johnson et al. 2001;
Lakatta 2003; Zieman et al. 2005], The age-related increase in collagen and thinning and
fragmentation of elastin has only been found in the elastic arteries [Nichols 2005].
Collagen in the aorta doubles in content between the ages of 20 to 70 years. In the skin,
a decrease in the voids of spaces between fibres with age results in more compact elastin
and collagen. The elastic fibres show signs of elastolysis while collagen bundles are
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randomly orientated and their numbers decreased [Tzaphlidou 2004], Elastin is found to
be fragmented with age in both arteries and skin.
In certain other diseases, however, although stiffness of arteries has been observed, no
studies have sought to establish a link with skin elasticity. Examples of such diseases are
diabetes [Cruickshank et al. 2002], hypertension [Boutouyrie et al. 2002b], left
ventricular hypertrophy [Deague et al. 2001], end-stage renal disease [Blacher et al.
1999b] and CAD [Lim et al. 2004a]. A similarity in both the skin and arteries is that
there is degeneration of elastin with a decrease in elasticity. If arterial stiffness or a
reduced arterial elasticity is found to correlate positively with reduced skin elasticity,
skin elasticity measures may be developed as representative external markers of arterial
stiffness and cardiovascular risk. This would also provide a simple non-invasive
technique that can be easily applied in a clinical setting. However, there are a number of
dissimilarities between the skin and arteries. One such dissimilarity is that in the skin
about 70% of dermal collagen is type I collagen and 15% is type III collagen [Silver et
al. 2001b]. These ratios are reversed in arteries [Champion et al. 1998]. In addition, in
the arteries collagen content increases with advancing age, however, collagen content in
the skin is found to decrease with age [Tzaphlidou 2004].
In this chapter, the association between skin elasticity and arterial elasticity was
examined (as arteries become less elastic they are described as having an increase in
stiffness). Moreover, one of the intentions of this study was to identify which anatomical
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skin region (for example leg, arm or back) showed the strongest relationship with
arterial stiffness.
The present study was carried out to determine:
1. if there is an association between arterial stiffness and skin elasticity, independent of
age,
2. if there is an association, which measure most accurately matched arterial stiffness




Healthy volunteers between the ages of 18 - 80 years were recruited through
advertisements placed at the local churches and at the Western General Hospital,
Edinburgh. Subjects were divided into age groups of 18 - 29, 30 - 39, 40 - 49, 50 - 59,
60 - 69 and 70 - 79. Female subjects were studied on days 7 - 28 of their ovulation
cycle to reduce the effect of hormonal changes on skin measurements [Berardesca E et
al. 1989], We aimed to recruit 20 subjects in each age group. Exclusion criteria were the
presence of skin disorders, sun burn and excessive exposure to ultraviolet radiation. In
addition, subjects were excluded if they were taking corticosteroids, on long term
medications or had recently taken antibiotics.
4.2.2 Measurements
Arterial stiffness of each subject was measured using each of the techniques of PWV,
PWA and the DVP. The technique of applanation tonometry with a high-fidelity
micromanometer (SPC-301, Millar Instruments, Texas, USA) was used to detect the
carotid, radial and femoral pressure waves. These waveforms were analysed using the
SphygmoCor® system software (Mx Aortic Blood Pressure Monitoring System, AtCor
Medical, Sydney, Australia, version 6.31) from which PWV and PWA were determined.
PWA comprised measurements of central AIx, AIx75, and PAIx. The DVP wave was
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determined by the Pulse Trace® (Micro Medical, Gillingham, Kent, United Kingdom), a
high fidelity finger plethysmography, from which the SI and the RI are derived. Non¬
invasive blood pressure measurements were carried out on the right arm using a
validated oscillometric technique (HEM-705CP; Omron Corporation, Japan)
A Cutometer® (Courage and Khazaka, Koln, Germany) which uses a vacuum suction
technique was used to measure waveforms of vertical skin deformation as a function of
time. An 8 mm diameter probe was used, through which a controlled vacuum force of 45
kPa was applied for 5 seconds and reduced to 0 mbar for 3 seconds. This cycle was
repeated 10 times. Ratios R2 (gross elasticity), R5 (neto-elasticity of the skin without
viscous deformation), R6 (ratio of visco-elastic to elastic distension) and R7 (biological
elasticity) were derived from these waveforms to determine elasticity of the skin as
shown in Figure 4-1. Details ofmethods used can be found in Chapter 2.
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Figure 4-1 Skin elasticity curve derived using a suction probe.
This figure represents skin deformation plotted as a function of time. A negative
pressure of 450 mbar is applied for 5s, followed by a 3-s relaxation period. This is
repeated 10 times. Ue denotes immediate distension; Uv, delayed distension; Uf, final
distension (skin distensibility); Ur, immediate retraction; Ua, final retraction and R,
residual deformation at the end of a measuring cycle (resilient distension). The skin
elasticity ratios are calculated from the absolute skin elasticity parameters whereby R2 =
Ua/Uf, R5 = Ur/Ue, R6 = Uv/Ue and R7 = Ur/Uf.
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4.2.3 Study protocol
All studies were carried out in a quiet temperature controlled room (22 - 25°C) after a
brief period (at least 20 minutes) of rest. Subjects were required to abstain from alcohol
24 hours before the study and cigarettes on the day of the study. Subjects were also
asked not to use cosmetics, moisturisers or moisturising baths on the day of the study.
Three brachial blood pressure recordings were measured 5 minutes apart to give the
mean baseline blood pressure. PWV, PWA and DVP recordings were made sequentially
at 5 minute intervals with a blood pressure recording before each measurement. This
was followed by measurements of skin elasticity on the dorsal forearm, ventral forearm,
upper arm, the top third of the upper leg and the upper back above the scapula. The
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4.2.4 Blood sampling and assays
Thirty mL of venous blood was obtained on the day of the study for routine biochemical
analysis. Blood samples were collected into tubes containing serum gel and potassium
EDTA (Monovette®, Sarstedt, Numbrecht, Germany), and kept on ice for less than 10
minutes before being centrifuged at 2,000 g for 30 minutes at 4°C. The serum was
decanted and stored at -80°C before being assayed by the clinical biochemistry
laboratory. LDL-C concentration was calculated using the Friedewald equation
[Friedewald et al. 1972].
4.2.5 Data analysis
Statistical analysis was performed using Microsoft Excel 2002 and SPSS version 11.5
for Windows program (SPSS, Inc., Chicago, IL, USA). Data are expressed as mean ±
SD. In addition to this, each subject's arterial stiffness measure was calculated as the
average of 3 individual measurements. Correlation between variables was evaluated
using Pearson's correlation coefficients. Variables that were related in univariate
analysis were further analysed in multivariate analysis using stepwise multiple
regression analysis. All testing was 2 sided and significance was taken at the 5% level.
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4.3 RESULTS
Baseline subject characteristics are shown in Table 4-1. Twenty people were recruited
in the age groups 18 - 29, 30 - 39, 40 - 49 and 50 - 59, while 18 people were recruited
in the 60 - 69 age group and 5 people in the 70 - 79 age group. Nine subjects were on
hormone replacement therapy and more than two thirds of subjects were non-smokers.
Skin elasticity ratios correlated well with stiffness measures as shown in Table 4-2 and
were also found to correlate with central mean blood pressure and LDL-C concentration.
When these variables were entered into multiple regression analysis, the upper leg R6
and R2 ratios and the ventral arm R6 value were the only determinants of arterial
stiffness measures. The upper leg R6 ratio was a consistent but weak determinant of
PWV, AIx, PAIx and RI. The upper leg R2 ratio was found to determine PWV and the
ventral arm R6 ratio was found to determine PAIx, but again both were weak
contributors. The regression equations and the respective scatter plots are shown in
Figure 4-3, Figure 4-4 and Figure 4-5.
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Table 4-2 Correlation between skin elasticity ratios and arterial stiffness measures.
Area of skin Ratio PWV AIx AIx75 PAIx SI RI
Back R2 -0.25* -0.27** -0.29 ** -0.23* -0.33** -0.08
R5 -0.56** -0.54** -0.60 ** -0.51** -0.57** -0.14
R6 0.37** 0.42** 0.42 ** 0.38** 0.45** 0.23*
R7 -0.58** -0.57** -0.62 ** -0.54** -0.60** -0.17
Dorsal arm R2 -0.46** -0.46** -0.48 ** -0.45** -0.42** -0.14
R5 -0.45** -0.51** -0.52 ** -0.49** -0.46** -0.14
R6 0.33** 0.31** 0.32 ** 0.30** 0.26** 0.19
R7 -0.49** -0.54** -0.55 ** -0.51** -0.48** -0.18
Ventral arm R2 -0.41** -0.43** -0.42 ** -0.43** -0.41** -0.18
R5 -0.51** -0.49** -0.52 ** -0.49** -0.45** -0.14
R6 0.31** 0.43** 0.39 ** 0.46** 0.41** 0.31**
R7 -0.53** -0.54** -0.56 ** -0.55** -0.50** -0.20*
Upper arm R2 -0.39** -0.48** -0.48 ** -0.46** -0.41** -0.23*
R5 -0.47** -0.59** -0.58 ** -0.57** -0.50** -0.27**
R6 0.30** 0.22* 0.24 * 0.23* 0.29** 0.14
R7 -0.49** -0.58** -0.58 ** -0.56** -0.52** -0.26**
Upper leg R2 -0.31** -0.43** -0.41 ** -0.42** -0.39** -0.23*
R5 -0.52** -0.52** -0.55 ** -0.52** -0.55** -0.16
R6 0.31** 0.52** 0.50 ** 0.53** 0.39** 0.38**
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4.4 DISCUSSION
Our results show that arterial stiffness is weakly associated with skin elasticity and this
is independent of age. By far the biggest predictor of arterial stiffness was age,
contributing about 60% of the variance. Measurements of skin from the upper leg
represented measurements which most consistently correlated to arterial stiffness
measures, independent of age, but it is less convenient as a clinical measure compared to
the other regions. Of the 4 skin elasticity ratios, the R6 ratio was a consistent contributor
but only by about 2%.
A number of previous studies have investigated relationships between various measures
associated with the mechanical properties of both the skin and arteries. One such study
by Uiterwaal et al. [Uiterwaal et al. 2003] found PP, a partial surrogate for arterial
stiffness, to decrease with an increase in skin extensibility and DBP to decrease with an
increase in joint mobility. Changes in connective tissue have also been found to occur in
both the arteries and the skin of patients with cervical artery dissections [Brandt et al.
2001] and intracranial aneurysms [Grond-Ginsbach et al. 2002]. However, there have
been studies which have not established an association between the pathological change
in arteries and skin which are less elastic. One such study found aortic stiffness, in
diabetics with CAD, to correlate with collagen linked fluorescence (a measure of
advanced glycosylated end products) in the aorta and myocardium but not in the skin
[Airaksinen et al. 1993]. They found the level of fluorescence, both in the myocardium
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and aorta, to be twice as high as that measured in the skin. This difference may partially
be explained by the differing ratios of Type I and Type III collagen in the skin and blood
vessels. Our study is, however, the first to attempt to investigate the relationship
between arterial and skin elasticity.
The dissimilar structural arrangement and response to low strains between the arteries
and skin possibly explains its weak (2%) association. At low strains, the elastic
component of the aorta in both the transverse and longitudinal direction is greater than
the viscous component. However, in the skin the viscous component contributes equally
to the elastic component [Dunn et al. 1983]. As the strain increases in the aorta there is a
decrease in the stress from the elastin component with a shift to an increase in the
contribution from the viscous component. The opposite is true for the skin, whereby the
stress from the elastin component increases with an increase in strain. Moreover, in both
the skin and aorta the curve of the elastin component is exponential and that of the
viscous component is linear which may also explain the weak linear relationship in both
skin and arterial elasticity. In the aorta, elastic fibres are folded in concentric rings and
are connected axially by elastin [Silver et al. 2001b]. Collagen and elastin fibres are
found in the medial layer. At low strains the elastin lamellae unfold allowing the aorta to
deform easily, while at higher strains collagen is sufficiently stretched for it to take most
of the stress. In contrast, collagen fibres in the skin are randomly arranged, and deform
in the direction of the applied stress [Silver et al. 2003]. The large viscous energy in skin
allows alignment of the collagen fibres along the stress axis without injury to the fibre-
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interfibrillar matrix interfaces. The differences in force contributions from elastin and
collagen in the aorta and the skin highlight different structural arrangements in these
tissues. Moreover, vascular diseases for example hypertension, may affect the force
contributions of either or both the elastic and viscous components at varying strains.
In addition to looking at the relationship between the skin elasticity ratios and arterial
elasticity, this sudy was an attempt to find skin regions which gave the strongest
relationship. The upper leg skin measurements were most closely correlated with arterial
elasticity measures. The skin of the upper leg is less exposed to extrinsic factors, such as
ultraviolet radiation, and therefore changes in its connective tissue may most closely
parallel structural changes in the vascular extra-cellular matrix. However, measurements
from the upper leg are not a convenient method of assessing skin elasticity in a clinical
setting.
Of the 4 skin ratios studied, the R2 and R6 showed a correlation with PWV, but the R6
ratio is considered a better determinant of the two as it correlates with a larger number of
stiffness parameters after age has been accounted for. Our findings support those of Cua
et al. who have previously shown the R6 ratio, of the 4 ratios, to be the least dependent
on age [Cua et al. 1990]. The R6 ratio, also called the viscoelastic-to-elastic ratio,
compares the delayed to the immediate deformation. The R2, R6 and R7 ratios account
for the viscous component of skin deformation unlike the R5 ratio and these ratios may
therefore better illustrate elasticity of skin. The elastic component is thought to relate to
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the stretching of the collagen and elastic fibres and the viscoelastic part, to the
movement of interstitial fluid through the fibrous network [Dobrev 2002],
Associations between skin elasticity and arterial stiffness are more dominant in people
who are genetically predisposed to either enzymatic changes in collagen and elastin
structure or metabolic changes. The enzymatic changes can be caused by any of the
following: growth factors, cytokines [Tayebjee et al. 2003], MMPs, TIMPs, hormones
and mechanical stress [Kingwell et al. 2001; Lakatta 2003]. Metabolic changes can lead
to changes in connective tissue as seen, for example, in diabetics [Airaksinen et al.
1993] who have high glucose concentrations causing non-enzymatic glycation of
proteins. Non-enzymatic glycation of proteins results in the cross-linking of collagen
fibres, which can alter the mechanical function of the artery and cause proteins that are
normally flexible to become rigid. In these groups of people it is likely that structural
changes in the arteries are most strongly related to skin elasticity.
Age plays an important role in the stiffening of arteries and loss of elasticity of the skin.
Arterial stiffness has been shown to increase steeply between the ages of 50 to 70 years
[Mitchell et al. 2004b]. However, there are insufficient data to draw conclusions on the
rate of stiffening after the age of 70 years. PP, a surrogate measure of arterial stiffness,
has also been shown to increase rapidly between the ages of 50 and 80 years after which
it reaches a plateau [Franklin et al. 1997], Central AIx has a curvilinear relationship with
age, which flattens out after the age of 60 years [O'Rourke et al. 2005]. In contrast, skin
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elasticity decreases with age but more rapidly after the age of 70 years [Balin et al.
1989]. This effect of age may obscure changes in skin and arterial elasticity due to other
pathological causes. Therefore, in older patients skin elasticity may not be an
appropriate marker of changes in arterial elasticity.
4.4.1 Study limitations
There are a number of limitations of our study. First, there were smaller numbers of
women in this study in the older age group which may affect interpretation of the
relationship between arterial and skin elasticity in this group. Second, there was a
difficulty recruiting healthy subjects between the ages of 60 to 80 years because a high
proportion of people between these ages were on long term medications. This age group
is important to this study in order to evaluate the relationship between skin and arterial
elasticity in older patients.
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4.5 CONCLUSIONS
Skin elasticity is not a useful predictive means of assessing arterial stiffnss indirectly.
Moreover, the upper leg dermal skin which was most strongly related to the extra¬
cellular matrix of the aorta is not a practical region of the body from which
measurements can be made in a clinical setting.
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CHAPTER 5: DETERMINANTS OF ARTERIAL STIFFNESS IN PATIENTS WITH
CORONARY ARTERY DISEASE
5.1 INTRODUCTION
Arterial stiffness is the rigidity of the vascular wall, which causes the artery to offer
more resistance to deformation and flow [Nichols et al. 1998]. Arterial stiffness is
determined by the structure and function of the vascular wall. The structural elements
responsible for the stiffness of the vessel are mainly elastin and collagen [Glasser et al.
1997]. Structural modification of the collagen and elastin matrix [Tayebjee et al. 2003]
leads to changes that alter PWV, wave reflection and vessel compliance [Avolio et al.
1998]. Furthermore, vascular smooth muscle cells, neurohumoral factors and
endothelium-derived factors can induce dynamic changes in arterial stiffness through
functional alterations in vessel tone [Glasser et al. 1996],
In young healthy people, blood is ejected from the left ventricle into the aorta which
generates a forward-travelling pressure wave or an incident wave [O'Rourke et al. 2002].
This incident wave travels towards the periphery and may be reflected at points of
discontinuities of the arterial wall, branching points of arterioles or vessel bifurcations.
The reflected wave travels back towards the aortic root and overlaps with the diastolic
phase of the incident wave. Therefore, the blood pressure wave is a composite of both
the incident and reflected pressure waves. However, as the arteries become stiff this
leads to the pressure wave propagating at a higher velocity [Nichols et al. 1998]. This in
i
turn causes the reflected wave, which would normally return during diastole, to occur
earlier during systole. This early return of the pressure wave increases aortic and
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ventricular pressures during systole and reduces aortic pressure during diastole [Safar et
al. 2003], High central systolic pressures increase the workload of the heart and lead to
the development of left ventricular hypertrophy [Deague et al. 2001], and low diastolic
pressures reduce coronary artery perfusion [Mackenzie et al. 2002; Nichols et al. 1998],
Arterial stiffening and an early return of wave reflections, with the disappearance of the
aortic-to-peripheral pressure amplification, is uncommon in people under 60 years of
age, but it is particularly common in patients over 40 years of age with end-stage renal
disease (ESRD). Arterial stiffness has been associated with vascular diseases, such as
CAD [Gatzka et al. 1998], and measures of arterial stiffness, such as PWV, predicts all-
cause and cardiovascular mortality in patients with ESRD [Blacher et al. 2003; Safar et
al. 2002] and hypertension [Boutouyrie et al. 2002a; Laurent et al. 2001; Laurent et al.
2003], However, the relationship between renal function and arterial stiffness in patients
with CAD, in the absence of a history of renal disease has not previously been studied.
Moreover, the association between non-invasively determined central arterial stiffness,
in patients with underlying CAD, with cardiovascular and all-cause mortality,
hospitalisation or revascularisation procedures is unknown.
Creatinine clearance, a surrogate measure of renal function, is a predictor of death in
patients with acute coronary syndrome [Santopinto et al. 2003] and a predictor of renal
failure and hospital morbidity in patients undergoing CABG [Noyez et al. 2006].
Estimated glomerular filtration rate (eGFR), a more accurate measure of renal function,
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is a predictor of mortality in patients experiencing an acute coronary syndrome
[Masoudi et al. 2004; Schiele et al. 2006], and mortality [Hillis et al. 2006] or
postoperative complications [Cooper et al. 2006] following a CABG. However, there is
limited information [Beddhu et al. 2002] on the association between renal function and
adverse fatal and non-fatal cardiovascular related outcomes in patients with CAD.
In a cohort of patients with CAD on treatment, we aimed to determine:
1. the relationship between arterial stiffness and measures of cardiovascular risk
including renal function.
2. the relationship between the presence of CAD, renal function, and arterial stiffness,
with major adverse cardiovascular events defined as cardiovascular and all-cause
mortality, hospitalisation due to cardiovascular causes (including non-fatal myocardial




Patients who had undergone elective cardiac catheterisation at the Western General
Hospital and the Royal Infirmary, Edinburgh were recruited into this study. Patients
were excluded if they had either marked left ventricular impairment (ejection fraction <
25%), significant valvular heart disease, critical aortic stenosis or a history of renal
disease. All studies were carried out at the Wellcome Trust Clinical Research Facility at
the Western General Hospital and the Royal Infirmary, Edinburgh. Subjects who
participated in this study attended a visit a week after cardiac catheterisation or at least 3
months after a coronary revascularisation procedure, such as CABG or percutaneous
transluminal coronary angiography (PTCA).
5.2.2 Measurements
PWV and PWA were carried out using the SphygmoCor® system (SphygmoCor® Mx,
AtCor Medical, Sydney, Australia, version 6.31). This system uses the technique of
applanation tonometry, in which a high-fidelity micromanometer (SPC-301, Millar
Instruments, Texas, USA) is used to determine carotid-femoral PWV. For PWA a probe
containing piezoelectric pressure sensors (Colin® 7000, Colin Medical Technology
Corporation, Japan) was used to derive the central aortic pressure waveforms from the
radial pressure waveforms. These central waveforms were used to determine central
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(AIx and AIx75) and peripheral (PAIx) augmentation indices. The SI and RI were
calculated from the DVP recorded by Pulse Trace (Micro Medical, Gillingham, Kent,
United Kingdom), which uses a high fidelity finger photoplethysmograph. Non-invasive
blood pressure measurements were carried out on the right arm using a validated
oscillometry technique (HEM-705CP, Omron Corporation, Japan). Details of the
methods used are described in Chapter 2.
5.2.3 Study protocol
Subjects were asked to omit their morning medications on the day of the study. Three
brachial blood pressure recordings were made 5 minutes apart to give the mean baseline
blood pressure. This was followed by PWV, DVP and PWA measurements made
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Figure 5-1 A schematic of the arterial stiffness study protocol.
The downward arrow, 1, denotes an arterial stiffness measurement.
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5.2.4 Outcomes
Subjects were followed up for fatal and non-fatal events as described in Section 2.6.
5.2.5 Blood sampling and assays
Ten mL of venous blood was obtained on the day of the study and collected into tubes
containing potassium EDTA (Monovette®, Sarstedt, Numbrecht, Germany). Routine
clinical biochemistry analyses were performed by the regional clinical laboratories.
LDL-C concentration was calculated using the Friedewald equation [Friedewald et al.
1972].
5.2.6 Data analysis
Each arterial stiffness datum point is the mean of 3 measurements. Statistical analyses
were performed using Microsoft Excel 2002 and SPSS version 11.5 for Windows
program (SPSS, Inc., Chicago, IL, USA). There were no violations in the assumptions of
normality, linearity, and homogeneity of variances. Data are expressed as mean ± SD.
All parametric data were analysed using Student's Ttest, ANOVA, and ANCOVA where
appropriate. Subjects had their renal function assessed based on serum creatinine
concentrations from biochemical blood analysis and estimated glomerular filtration rate
calculated using the Cockcroft and Gault equation [Cockcroft et al. 1976] (eGFRcG )
eGFRcG = k[[140 - age (yr)] x weight (kg)]/ SrCr (/xmol/L)
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where SrCr is serum creatinine concentration, and A: is a value of 1.22 for males and 1.04
for females. The GFRcg was corrected for body surface area (BSA) using the estimated
BSA according to Du Bois and Du Bois [Du Bois et al. 1916] by the formula
BSA = weight (kg)0'425 x height (m)0'725 x 0.20247
Corrected eGFR = eGFRCG/BSA x 1.73
Subjects were grouped into eGFR groups based on the National Kidney Foundation
Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines of staging eGFR in
chronic kidney disease (CKD). Subjects were classed into eGFR stages 1 to 3 as none of
the subjects had eGFR values less than 30ml/min. GFR calculated using the Cockcroft
and Gault equation has been shown to be more accurate than the Modification of Diet in
Renal Disease (MDRD) equation in patients not known to have chronic kidney disease
[Poggio et al. 2005; Rule et al. 2004], Serum creatinine concentrations (range 52 - 165
/xmol/L) and eGFR (38.2 - 122.8 ml/min) were available in 282 subjects.
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5.3 RESULTS
Of the 288 participants, 4 were excluded due to technical difficulties. The augmentation,
stiffness and reflection indices were available in 284 subjects. The remaining 284
participants (210 men and 74 women with a mean age of 62 ± 8 years) comprised 35
(12.6%) subjects with angiographically normal coronary arteries (Table 5-1 and Table
5-2). Satisfactory PWV recordings were only available in 245 subjects.
5.3.1 Demographic and anthropometric factors
In univariate analysis, PWV and AIx increased with age (Table 5-3). Women had higher
augmentation indices (AIx, 39 ± 9 vs 33 ± 9, P < 0.001; AIx75, 32 ± 8 vs 24 ± 8, P <
0.001; and, PAIx, -5 ± 14 vs -9 ± 13, P < 0.05) although men had higher SI values (11 ±
3 vs 9 ± 2, p=0.001). No difference in PWV was found between men and women. BMI
positively correlated with PWV but negatively correlated with AIx, AIx75, PAIx, SI and
RI.
5.3.2 HAEMODYNAMIC FACTORS
Heart rate positively correlated with PWV (r = 0.20, P < 0.01) and inversely correlated
with AIx (r = -0.39, P < 0.001), PAIx (r = -0.38, P < 0.01) and RI (r = -0.38, P < 0.01).
Subjects with high systolic and mean blood pressures had high PWV, AIx, AIx75 and
PAIx measures. In addition, subjects with high PWV, AIx75 or SI measures had high
diastolic pressures.
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Table 5-1 Baseline subject characteristics of the arterial stiffness study.
No CAD CAD Total
(N=35) (N=249) (N=284)
Demographics
Age, y (range 41-80) 59 ±9 62 ±8 62 ±8
Men/Women 15/20 195/54 210/74
Height, cm 169 ±9 170 ±9 169 ±9
Weight, kg 82 ± 14 82 ± 15 82 ± 14
Body mass index, kg/m2 28 ±4 29 ±5 29 ±4
Biochemistry
Serum creatinine, pmol/L (52 - 165) 85 ± 12 95±18** 94 ± 18
Estimated glomerular filtration rate, ml/min 76 ± 14 73 ± 17 74 ± 17
(range 38.2- 122.8)
Total cholesterol, mmol/L 5 ± 1 5.0 ±1.1* 5 ± 1.1
HDL cholesterol, mmol/L 1.5 ±0.4 1.2 ± 0.3f 1.2 ±0.3
LDL-C, mg/dL 111 ±39 98 ±37 100 ±37
Triglycerides, mmol/L 1.5 ±0.7 1.9 ± 1.0* 1.9 ± 1.0
ChokHDLC ratio 3.7 ± 1.2 4.0 ± 1.1 4.0 ±1.1
Haemodynamics
Peripheral SBP 132 ± 18 133 ± 17 133 ± 17
Peripheral DBP 76 ±9 75 ± 10 75 ± 10
Peripheral MBP 96 ± 12 96 ± 12 96 ± 12
Central SBP 125 ± 18 126 ± 17 126 ±17
Central DBP 77 ±9 76 ± 10 76 ± 10
Central MBP 76 ± 12 96 ± 12 96 ± 12
Heart rate, bpm (40-89) 60 ±7 58 ±9 58 ±9
Pulse wave velocity, m/s 9.2 ±3.1 9.6 ±2.2 9.5 ±2.4
Augmentation index, % 34 ±9 34 ±9 34.4 ±9.2
Augmentation index at a HR75, % 27 ±9 26 ±8 26.3 ±8.5
Peripheral augmentation, % -10± 12 -7.4 ± 13.5 -7.7 ± 13.3
Stiffness Index, m/s 10 ± 3 10.5 ±3.3 10.5 ±3.3
Reflection Index, % 77 ±9 79.5 ± 14.0 79.2 ± 13.5
Values are means ± SD. SBP denotes systolic blood pressure; DBP, diastolic blood
pressure; MBP, mean blood pressure. * P < 0.05, **P < 0.01, f P < 0.001 versus no
CAD.
171
Table 5-2 Clinical and therapeutic profile of the subjects.
No CAD (N=35) CAD (N=249) Total (N=284)
Canadian Cardiovascular Society Classification
Class 1 71.4(25) 51.4(128) 53.9(153)
Class 2 20 (7) 35.3 (88) 33.5 (95)
Class 3 8.6 (3) 11.6 (29) 11.3 (32)
Class 4 0 1.6(4) 1.4(4)
Vessel Disease
Normal/no plaque 100 (35) 12.3 (35)
1 vessel 28.5 (71) 25.0 (71)
2 vessels 37.8 (94) 33.1(94)
3 vessels 33.7 (84) 29.6 (84)
Past medical history
Current smokers 14.3 (5) 15.3 (38) 15.1 (43)
Ex-smokers 45.7 (16) 47.8(119) 47.5 (135)
Non-smokers 40(14) 36.9 (92) 37.3 (106)
Hypercholesterolaemia 77.1 (27) 81.9(204) 81.3 (231)
Diabetes
Type I 0 1.2 (3) 1.1 (3)
Type II 2.9(1) 10.8 (27) 9.8 (28)
Hypertension 48.6(17) 55.8 (139) 54.9(156)
Myocardial Infarct 17.1 (6) 36.5 (91) 34.2 (97)
Heart failure 0 4.8(12) 4.2 (12)
Stroke 8.6 (3) 5.6(14) 34.2 (97)
Drug Therapy
Diuretics 25.7(9) 21.7 (54) 22.2 (63)
jS-blocker 40(14) 70.3 (175) 66.5 (189)
Nitrates 40(14) 73.9 (184) 69.7(198)
ACE inhibitors 17.1 (6) 38.6 (96) 35.9(102)
Calcium channel blocker 40(14) 28.1 (70) 29.6 (84)
Angiotensin receptor blocker 5.7 (2) 4.4(11) 4.6(13)
Nicorandil 2.9(1) 19.3 (48) 17.3 (49)
Statin 60 (21) 91.2 (227) 87.3 (248)
HRT 5.7 (2) 2.4 (6) 2.8 (8)
Hypercholesterolaemia was indicated by a previous diagnosis or the use of a cholesterol-
lowering agent. Patients were classified as having diabetes, hypertension, ischaemic
heart disease, myocardial infarct or heart failure indicated by a previous clinical
diagnosis. Values shown are in % (n).
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5.3.3 Renal function
PWV correlated inversely with eGFR and positively with serum creatinine
concentration (Figure 5-2 and Figure 5-3). The inverse relationship between PWV
and eGFR (r = 0.04, P < 0.01) persisted in subjects with normal renal function (eGFR
> 60ml/min). These correlates with PWV were not found with augmentation,
stiffness or reflection indices.
5.3.4 Diabetes
Subjects with diabetes had a higher mean PWV compared to subjects without
diabetes (10.5 ± 2.4 vs 9.4 ± 2.3), but had a lower mean AIx (30.9 ± 11.1 vs 34.8 ±
8.8), and RI (72.9 ± 17.1 vs 80.0 ± 12.8) after controlling for mean blood pressure (P
< 0.05; ANCOVA). The ejection duration was shorter for those subjects with
diabetes (355 ± 28 vs 340 ± 28; P < 0.01; ANCOVA).
5.3.5 Angina severity and extent of coronary artery disease
Subjects with or without CAD had very similar profiles (Table 5-1). Subjects with
CAD had a lower mean HDL-C concentration (Table 5-1). There were no
differences in serum creatinine concentrations or eGFR between groups (Figure 5-4).
There were no differences in PWV and no consistent relationships between
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Figure 5-2 Arterial stiffness and renal function in all subjects.
Scatterplot of PWV versus (a) serum creatinine concentration and (b) glomerular











Estimated glomerular filtration rate group
eGFR group 1 - 14.4 % (N=41)
eGFR group 2-63.4 % (N=180)
eGFR group 3 - 19 % (N=54)
Figure 5-3 Relationship between arterial stiffness and renal function groups.
PWV for subjects grouped according to tertiles of glomerular filtration rate. The
glomerular filtration rate for group 1, >90 ml/min; group 2, 60 - 89 ml/min; and
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Figure 5-4 (a) Estimated glomerular filtration rate and (b) pulse wave velocity
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5.3.6 Drug effects on arterial stiffness measures
Nitrates, /3-blockers, calcium channel blockers, ACE inhibitors, angiotensin receptor
blockers, hormone replacement therapy (HRT) and statins did not affect arterial
stiffness measures. After adjusting for central mean blood pressure, total cholesterol,
and serum creatinine, patients on nicorandil had higher PWV (9.32 ± 0.2 vs 10.45 ±
0.3; P < 0.01; ANCOVA).
5.3.7 Multiple regression analysis
Variables that were found to be correlated in univariate analysis were further
analysed in multivariate analysis to determine the interaction of other variables.
Aortic PWV positively correlated with age, heart rate, central SBP, BMI and serum
creatinine concentration. These variables explained 38% of the variance in PWV
(Stepwise multiple linear regression analysis). PWV was negatively correlated with
central and peripheral augmentation indices in both univariate and multivariate
analysis. The determinants ofAIx, AIx75, and PAIx are shown in Table 5-4. None of
the independent variables were related with either SI or RI in multivariate analysis.
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Table5-4Multivariatean lysisofrterialstiffneme sur . Arterialstiffnessmeasure
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Follow-up was carried out in 284 subjects and ended on July 2, 2005 (mean follow-
up of 1.5 years). There were 6 deaths, 3 of which were due to a cardiovascular cause
and the remaining 3 were due to cancer. One subject had a stroke, 3 subjects had an
AMI and 99 subjects had CHD-related admissions. Age, sex, smoking status, blood
pressure, serum lipid or cholesterol concentrations were not associated with fatal and
non-fatal events. Subjects who had an event were older, had a lower eGFR and a
higher PWV compared to subjects who did not have an event.
5.3.8.1 Coronary artery disease severity as a predictor of outcomes
Subjects with ischaemic heart disease (IHD) had a shorter time to a composite end
point compared to subjects without IHD (Figure 5-6). Moreover, subjects with a
higher number of diseased coronary vessels had a shorter time to an event. The
severity of coronary vessel disease contributed to a shorter time to events (Table
5-6).
5.3.8.2 Renal function as a predictor of outcomes
Subjects who suffered an event had a lower eGFR (69 ± 16 vs 76 ± 16 mL/min; P <
0.001) and a higher serum creatinine concentration (98.1 ± 19.2 vs 92.2 ± 16.3
pmol/L; P < 0.01). Subjects who underwent coronary revascularisation had a higher
serum creatinine concentration (101.6 ± 19.2 vs 93.7 ± 17.4 pmol/L; P < 0.05; Mest)
but there were no differences in eGFR. When subjects were divided into stages of
eGFR, subjects with a lower eGFR had a shorter time to a composite end point (P <
0.01) (Figure 5-7). EGFR, in addition to coronary vessel disease severity, determined
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a shorter time to events (Table 5-6). Subjects in eGFR group 3 were older and had
higher peripheral and central SBP compared to eGFR group 2 and 3 (Table 5-7).
However, there was roughly an even distribution of subjects with varying severity of
CAD across the 3 groups (Table 5-8). A higher percentage of subjects in eGFR
group 3 were on ACE inhibitors. However, the percentage of subjects on other
classes of drugs were also roughly evenly distributed across the 3 groups. In subjects
with normal renal function (eGFR <60 ml/min) both the severity of coronary vessel
disease and eGFR (R2 = 0.064, P < 0.01) remained determinants of a shorter time to
fatal and non-fatal outcomes.
5.3.8.3 Arterial stiffness as a predictor of outcomes
Subjects who suffered an event had a higher PWV (9.9 ± 2.3 vs 9.3 ± 2.4 m/s; P <
0.05) compared to those without an event. Subjects with PWVs above the median
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Figure 5-7 Kaplan Meier plots of time to composite end point for all subjects
grouped by estimated glomerular filtration rate.
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Table 5-7 Demographic variables and blood pressures between estimated glomerular
filtration groups.






Age 52 ± 8#+ 62 ±8* 69 ± 5+
Peripheral SBP 123 ± 13#+ 134 ± 17 136± 19
Peripheral DBP 72 ± 8+ 76 ± 10 73 ± 10
Peripheral MBP 91 ±9+ 97 ± 12 95 ± 13
Central SBP 116 ± 13#+ 127 ± 17 129 ± 19
Central DBP 73 ±8 77 ± 10 74 ± 11
Central MBP 91 ±9+ 97 ± 12 95 ± 13
+,a significant difference to eGFR group 2; denotes a significant difference to eGFR
group 3
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Numbers of diseased coronary vessels
0 vessel 12.2 (5) 13.7(25) 5.6 (3)
1-vessel 29.3 (12) 24.7 (45) 24.1 (13)
2-vessel 29.3 (12) 31.3 (57) 44.4 (24)
3-vessel 29.3 (12) 30.2 (55) 25.9(14)
Drug therapy
/3-blocker 56.1 (23) 70.9 (129) 57.4 (31)
Nitrate 78 (32) 70.3 (128) 63 (34)
HRT 9.8 (4) 1.6 (3) 1.9(1)
Statin 87.8 (36) 87.4(159) 87 (47)
ACE-Inhibitor 29.3 (12) 35.2 (64) 44.4 (24)
Angiotensin receptor blocker 2.4(1) 5.5 (10) 3.7 (2)
Calcium channel blocker 39(16) 25.3 (46) 35.2(19)
Nicorandil 17.1 (7) 15.9 (29) 18.5 (10)
































L-R statistic = 5.46
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Duration of follow-up (days)
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PWV >9.13 group
Figure 5-8 Kaplan Meier plots of time to composite end point for subjects grouped
according to pulse wave velocities above and below the median pulse wave velocity.
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5.4 DISCUSSION
Two hundred and eighty four subjects with varying degrees of CAD were studied to
assess the determinants of central arterial stiffness in this group of patients. PWV, a
"gold standard" ofmeasuring arterial stiffness, was related to age, heart rate, central
SBP and serum creatinine concentration. Whilst standard cardiovascular risk factors
did not appear to be a major determinant in this treated group of patients with CAD,
serum creatinine concentration independently contributed to arterial stiffness in these
patients who did not have a history of renal disease. The presence and extent of CAD
was a predictor of adverse cardiovascular events, which is consistent with previous
findings. In addition, PWV and eGFR have been identified as predictors of adverse
cardiovascular outcome. Moreover, even for those subjects with normal renal
function eGFR remained an important determinant of cardiovascular outcome.
5.4.1 Age
In this study, PWV was strongly determined by age. This supports findings from
previous studies [Avolio AP et al. 1983; Mitchell et al. 2004a] and a recent large
study (N = 998) in healthy subjects [McEniery et al. 2005], where a larger increase in
PWV was found in older subjects whilst AIx was found to lose its discriminative
power in older subjects and a larger increase in AIx was found in younger subjects
(Figure5-9). PWV in older subjects is largely determined by a decrease in aortic
compliance or an increase in forward pressure wave amplitude rather than a change
in the reflected wave [Mitchell et al. 2004b]. Although in a small group of healthy
men SI appeared to be associated [Millasseau et al. 2003] there are no previous data
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Figure 5-9 Relationship of the AIx and PWV with age.
Regression curves representing the effect of age on parameters of arterial stiffness
and wave reflection for males (circles, solid lines) and females (squares, dashed
lines). Panel A represents augmentation pressure (open circles/open squares) and
augmentation index (closed circles/closed squares). Panel B represents aortic pulse
wave velocity. Data points are the group means for each decile of age. Taken from
McEniery et al. Normal Vascular Ageing: Differential Vascular Effects on Wave




Whilst there were no differences in PWV, augmentation and stiffness indices were
related to sex. Consistent with our findings McEniery et al. found no difference in
PWV between men and women, whereas AIx was consistently higher in women in
all age groups [McEniery et al. 2005], It is well established that the differences in
central augmentation pressure [Gatzka et al. 2001b; Smulyan et al. 2001] between
males and females are greater than the difference in PWV [Mitchell et al. 2004b]
between sexes. The disparity between PWV and the augmentation and stiffness
indices may be explained by a number of factors. First, the augmentation indices are
themselves determined by PWV. An increase in PWV increases the augmentation
indices because a greater proportion of the reflected waves arrive earlier during
systole. Second, females on average are shorter than males [Hayward et al. 1997].
Therefore the distance between the heart and sites of wave reflection, in females, is
shorter and leads to the reflected wave arriving earlier during the systolic phase. In a
previous study [McEniery et al. 2005], when AIx was corrected for height, females
were still found to have a higher AIx compared to men highlighting that other factors
also contribute [Gatzka et al. 2001b]. Third, left ventricular contractility, ejection
duration and the size and elasticity of small muscular arteries [Gatzka et al. 2001b;
Waddell et al. 2001] determine the intensity of wave reflections [Kelly et al. 2001].
Women have a smaller aortic diameter which results in a longer ejection time and
prolonged time to the systolic peak therefore resulting in an earlier overlapping of the
forward and reflected waves [Gatzka et al. 2001b],
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5.4.3 BLOOD PRESSURE AND HEART RATE
Despite previous findings showing aortic stiffness not to be associated with heart rate
[Wilkinson et al. 2002c], in this study subjects with high PWV measures had high
heart rates. There are a possible number of explanations for this discrepancy. First,
the high heart rates and the high BMI in subjects with high PWV measures may be
due to low physical fitness rather than being a cause of increased PWV. Second,
sympathetic activation may have resulted in the high heart rate and arterial stiffness
measures. In addition, cyclical stress, due to high heart rates, may result in
fragmentation of elastic fibres and replacement by collagen fibres [O'Rourke 1995].
This in turn may cause the arterial lumen to be dilated with a loss of elastic recoil
resulting in increased stiffness of the arterial wall [Nichols et al. 1998], However,
this study, unlike that of Wilkinson et al. [2002], uses epidemiological rather an
interventional approach and therefore cannot explain the underlying mechanistic
effect of heart rate on PWV. Other studies [Albaladejo et al. 2003; Lantelme et al.
2002] have shown an association between high PWV and high heart rates. However,
the relative benefits of calculating transit time between the different methodologies
as a cause of this relationship has been debated [Millasseau et al. 2005].
A lower AIx with higher heart rates, in this study, is consistent with previous studies
[Albaladejo et al. 2001; Wilkinson et al. 2000a] which report that an increase in
heart rate causes a decrease in the systolic duration with the reflected wave arriving
during the diastolic phase resulting in a decrease in AIx.
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5.4.4 Renal function
Patients with ESRF who have stiffer arteries are predisposed to cardiovascular
related deaths [Blacher et al. 2003], PWV is higher in subjects with low eGFRs and
it increases with the severity of CKD [Wang et al. 2005], A high serum creatinine
concentration and lower creatinine clearance has been described in subjects with
cardiovascular disease [Bortolotto et al. 1999b]. More recently, high PWV measures
have been found in untreated hypertensive subjects with low creatinine clearance
[Mourad et al. 2001] and treated hypertensive subjects with high serum creatinine
concentrations [Benetos et al. 2002; Blacher et al. 1999a]. Taken together, these
studies suggest there may be a relationship between renal function and arterial
stiffness in patients with underlying CAD, which I have investigated in this study.
The main finding of this analysis is that serum creatinine concentration and eGFR, in
patients with CAD, is associated with stiffening of the large central elastic arteries. A
number of explanations may be given for the causality of this relationship, however,
the association above cannot be assumed to establish a causal relationship. The high
stiffness measures may be a cause or effect of reduced renal function. In the former,
an increase in arterial stiffness leads to an increase in SBP resulting in high PP. The
high pressure waves generated can cause injury of the renal arteries or lower
glomerular numbers resulting in renal disease [Foutzenhiser et al. 2002; Mitchell
2004; Pedrinelli et al. 2000]. In the latter case, impaired renal function may lead to
stiffening of the large arteries through accumulation of advanced glycosylation end-
products due to its reduced elimination by the kidneys [Makita et al. 1991; Makita et
al. 1994], increased collagen cross-linking [Sell et al. 1990], sodium and fluid
imbalance [Yu et al. 1998] or increased activation of the renin-angiotensin-
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aldosterone system (RAAS) [Blacher et al. 1997]. More recently, renal function,
assessed by eGFR, has been found to positively predict cardiovascular death or
hospitalisation in patients with CHF [Hillege et al. 2006] and in CHF patients who
have CAD [Smilde et al. 2004], These studies highlight the prognostic significance
of eGFR in not only renal patients but in patients with cardiovascular disease.
The majority of subjects in this study had normal serum creatinine concentrations
which may be a result of reduced clearance of serum creatinine. Therefore the
corrected eGFR represented a better measure of renal function which accounted for
age, gender and calculated body surface area for individual subjects.
5.4.5 Cardiovascular and metabolic risk factors
No relationships were found with metabolic and established cardiovascular risk
factors. The lack of relationship between CAD and cholesterol and lipid
concentrations is very likely a reflection of the high use of statins, in approximately
90% of subjects. In this and other studies, patients with diabetes had a higher PWV
compared to patients without diabetes [Schram et al. 2004], However, in this study,
subjects with diabetes had a surprisingly lower AIx and RI. When AIx was corrected
for heart rate no difference was found between subjects with diabetes and those
without diabetes. A study by Lacy et al. found subjects with diabetes to have an
increase in PWV but no difference in AIx compared to subjects without diabetes
[Lacy et al. 2004] and this was also shown by Aoun et al. in a large study [Aoun et
al. 2001], These differences in PWV and augmentation indices may be explained by
shorter ejection duration, as was found in this study, or reduced wave reflection in
diabetics. Arterial pressure waveforms in diabetics may also be altered by structural
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changes such as changes in connective tissue composition or increased collagen
cross-linking due to advanced glycosylation end product (AGE) binding [Airaksinen
et al. 1993]. In contrast, other studies [Brooks et al. 2001; Wilkinson et al. 2000b]
have shown AIx to be higher in diabetics. However, these studies have been carried
out in either small sample numbers or in younger subjects. Arterial stiffness not only
correlates positively with coronary risk factors [McVeigh 2003; Nichols et al. 2002;
O'Rourke et al. 2002] but also with the presence of CAD [Hayashi et al. 2002;
Weber et al. 2004], In the present study, PWV was unrelated to the presence of or
extent of CAD while the augmentation indices were surprisingly negatively related
with the numbers of vessel disease. Atherosclerosis is a systemic disease but it may
affect different vascular beds to varying degrees. From these results, we can assume
that disease of the coronary arteries is not a measure of widespread atherosclerotic
plaque in the body or aortic atherosclerotic disease. The difference in association
between CAD with PWV and the augmentation measures may be explained by
factors such as heart rate, ejection duration, and wave reflection having a more
profound effect on augmentation measures.
5.4.6 Outcomes
5.4.6.1 Presence and severity ofCAD as a predictor of outcomes
The positive association between the presence and severity of CAD and adverse
cardiovascular outcomes provides reassurance that the cohort of subjects studied in
the present study was representative of patients with CAD. Moreover, these results
support previous findings [Harris et al. 1980; Proudfit et al. 1983; Waters et al.
1993] that the severity of coronary vessel disease as determined by coronary
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catheterisation is a prognostic indicator of adverse cardiovascular outcomes in
patients with CAD.
5.4.6.2 Renal function as a predictor of outcomes
An interesting finding was that a lower eGFR in these subjects, who do not have a
history of renal disease, predicted a shorter time to fatal and non-fatal events and
revascularisation procedures. More importantly, eGFR in subjects with normal renal
function was a determinant of a shorter time to adverse cardiovascular events. These
results indicate the importance of surrogate measures of renal function as prognostic
indicators in patients with CAD. The roughly even distribution of subjects according
to severity of CAD and distribution of drugs across the eGFR tertiles reinforces that
eGFR is an important prognostic indicator of fatal and non-fatal events in the
subjects who may be mistaken as being at a lower risk when assessing subjects
purely on severity of vessel disease.
Our findings support a previous study [Beddhu et al. 2002] carried out in patients
with CAD whereby eGFR was found to be a predictor of death, MI or a composite of
both death and MI. The latter study, however, comprised of patients who had stable
or unstable angina as well as subjects who had an acute MI. The present study built
on these findings by assessing the association between renal function and fatal and
non-fatal cardiovascular events, including hospitalisation in subjects with stable
angina. Renal disease is known to be a risk factor for adverse fatal and non-fatal
cardiovascular outcomes in subjects who experienced an acute MI [Anavekar et al.
2004], However, they included patients who also had heart failure or left ventricular
systolic dysfunction which may have confounded the predictive ability of eGFR in
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patients with stable angina. Recently, a study in a small number of patients with
CAD, who had normal GFRs, found a reduction in renal perfusion to be a marker of
progressive renal dysfunction [Fuiano et al. 2005], Subjects in our study had low
eGFRs and may have had impaired renal function. Flowever, neither renal perfusion
nor GFR was measured directly and therefore it is not known whether these subjects
did have renovascular disease.
In the present study, the presence of a lower eGFR may have been a cause or an
effect of atherosclerosis of the systemic and coronary arteries. The presence of a low
eGFR in some subjects, for example, may be an indicator of the presence of
atherosclerosis in the renal vascular bed. Renal function may have implications on
deteriorating cardiovascular function through increased arterial calcification,
anaemia, sodium and fluid imbalance, imbalance in calcium-phosphate homeostasis,
activation of the renin-angiotensin-aldosterone system (RAAS) and promotion of
coagulation. It is also possible that the presence of atherosclerosis or stiffening of the
systemic arteries may have lead to reduced perfusion of the renal arteries which in
turn may have indirectly had an effect on the vascular system via the above
mechanisms.
5.4.6.3 Arterial stiffness as a predictor of outcomes
When subjects were grouped above and below the median PWV, those subjects with
PWV values above the median were more likely to have a lower event-free
probability. Atherosclerotic changes in the aorta may lead to aortic stiffening as a
result of fibrosis, calcifications, diffusion of macromolecules into arterial wall and
fragmentation of elastin fibres due to cyclical stress. An increase in aortic stiffness
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can in turn increase the work the heart needs to undergo to pump blood from the left
ventricle into the aorta. Moreover, there is a reduction in the diastolic pressure,
which is necessary for perfusion of the coronary arteries, which may have resulted in
subjects with higher PWVs being more likely to suffer a cardiovascular event.
5.4.7 Arterial stiffness measures
The augmentation indices, SI and RI did not add any information to that provided by
PWV. In the measurement of the augmentation indices and RI it can be difficult to
detect the first and second systolic peaks of the arterial pressure waveform, which in
turn can hamper the accurate calculation of these indices [O'Rourke et al. 2004],
PWV, in the present study study, was solely determined by characteristics of the
large artery whereas the augmentation, SI and RI measures are affected by the
geometry of smaller arteries. Previous studies [Millasseau et al. 2000] on healthy
subjects and patients with hypertension have shown SI and RI to be useful measures
of arterial stiffness. The patients in our study, far from being healthy, had CAD and it
was found that the incident and reflected wave overlapped sufficiently for the peaks
to coincide and this gives a triangular waveform from which accurate measurements
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5.4.8 Study limitations
This study had a number of limitations. First, BMI is not an ideal measure of adiposity
as it does not take into account the contribution from muscle mass. An alternative for
future studies would be to measure the ratio of waist to hip circumference which is a
better indicator of body fat distribution [Peiris et al. 1989]. Second, eGFR calculated
from serum creatinine based equations may not be an accurate measure of GFR.
However, it has been shown to correlate strongly with measured GFR [Froissart et al.
2005]. Third, the comparator group was relatively small as less than 10% of subjects had
angiographically normal coronary arteries. It is well known that underlying intimal
atherosclerotic plaque that does not encroach on the lumen can produce a normal
looking artery on coronary angiography [Escolar et al. 2006]. However, more advanced
techniques such as intravascular ultrasound (IVUS) and magnetic resonance imaging
(MRI) are able to detect occult disease in angiographically normal sites [Nissen et al.
2001]. Therefore, this may be one explanation of why there were no significant
differences in the majority of the arterial stiffness measures between subjects with CAD
and those with angiographically normal coronary arteries, because these patients with
normal angiograms still have widespread atherosclerosis. In addition, subjects who do
not have CAD may have aortic, peripheral or renal disease which may explain why there
were no differences in arterial stiffness measures between those with and without CAD.
Finally, the number of deaths, AMIs and strokes were too small to be assessed as
separate end-points. However, due to the short period of follow-up to date a composite
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measure consisting of fatal and non-fatal events represented a good measure of
cardiovascular risk (see methods Section 2.6).
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5.5 CONCLUSIONS
In a treated population of patients with CAD, cardiovascular risk factors do not
determine arterial stiffness, whereas, renal function is an important determinant of
arterial stiffness. Estimated GFR was associated with PWV, even within the normal
range, suggesting that it would be useful to use eGFR as an additional risk marker in
patients, even within the normal range. However, more research is needed to verify renal
function as a marker of risk in patients with CAD. Alternative measures of arterial
stiffness were inferior to PWV and did not give similar information. The presence and
severity of CAD, arterial stiffness and renal function are important predictors of a
shorter time to fatal and non-fatal cardiovascular events.
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CHAPTER 6: NON-INVASIVE ASSSESSMENT OF ENDOTHELIAL FUNCTION
IN PATIENTS WITH CORONARY ARTERY DISEASE
6.1 INTRODUCTION
The endothelium is a single cell layer that regulates vasomotor tone, anticoagulant
activity, antiplatelet activity, blood flow and vascular smooth muscle cell proliferation
[Davignon et al. 2004]. Vasomotor tone is regulated by both contracting (endothelin-1,
angiotensin II) and relaxing factors (NO, endothelium-derived hyperpolarising factor
(EDHF), prostacyclin). The endothelium is activated by a number of substances such as
autocoids and catecholamines, as well as shear stress produced by increased blood flow
[Harris et al. 2004], Traditional risk factors such as hypercholesterolaemia,
hypertension, diabetes, and smoking have been associated with an impairment in
endothelium-dependent vasomotor function [Vita et al. 1990], Endothelial dysfunction is
found in the presence of mild and advanced CAD [Ludmer et al. 1986] and is present
early on in life in children with risk factors for atherosclerosis [Celermajer et al. 1992].
Endothelial function can be assessed by exposing blood vessels to drugs that mediate
their vasodilatory effect through the release of NO from the endothelial cell layer. For
example, ACh is thought to act on the muscarinic M3 receptor present on endothelial
cells [Bruning et al. 1994], The M3 receptors couple with the heterotrimeric G protein
Gq which leads to an increase in intracellular calcium through the stimulation of
phospholipase C [Eglen et al. 2001] and the release of inositol (l,4,5)-triphosphate,
which results in the release of NO. However, if endothelial function is impaired there is
reduced production ofNO, increased degradation ofNO or both. Reduced production of
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NO causes vasodilatation, or increased vasoconstriction, of the coronary circulation in
response to ACh. In addition, degradation of NO may be accelerated through its
interaction with superoxide anions [Tentolouris et al. 2000] resulting in less NO
available to smooth muscle cells, which in turn leads to reduced vasodilatation.
As detailed in Chapter 1, there are a number of invasive [Ludmer et al. 1986; Vita et al.
1990] and non-invasive [Celermajer et al. 1992; Lauer et al. 2005] techniques that can
be used to assess endothelial function. In this study, endothelial function was
investigated using the technique of applanation tonometry in combination with the
administration of GTN and salbutamol. As blood is ejected from the left ventricle, the
pressure pulse wave generated travels along the aorta and the small muscular arteries.
These small muscular arteries offer resistance and cause reflection of these pressure
waves back to the aorta. Vasodilators such as GTN are able to reduce the amount of
wave reflection by decreasing the resistance of the small muscular arteries and causing
the reflected wave to return later during diastole. The reduction in resistance of the small
muscular arteries is mediated by denitration of GTN in the smooth muscle cells which
results in the release of NO from GTN [Abou-Mohamed et al. 2000]. This in turn
activates smooth muscle guanylyl cyclase and subsequently leads to the accumulation of
cyclic guanosine monophosphate (cGMP) causing relaxation of smooth muscle cells.
Therefore, GTN causes vasodilatation through its action on the smooth muscle cells.
However, the vasodilatory effect of GTN is dependent on the sensitivity of smooth
muscle cells to NO [Gori et al. 2001], and the bioavailability and degradation of NO
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[Abou-Mohamed et al. 2000]. Salbutamol is another vasodilator that reduces wave
reflections by reducing the resistance of small muscular arteries. Salbutamol induced
reduction in wave reflection is mediated through the endothelium and is, therefore, a
measure of endothelial function. Salbutamol, a selective ft-agonist, reduces wave
reflection in part by activation of the L-arginine/NO pathway [Dawes et al. 1997;
Hayward et al. 2002] which leads to the release ofNO from endothelial cells which in
turn activates smooth muscle guanylyl cyclase and causes vasodilatation [Chowienczyk
et al. 1999; Dawes et al. 1997]. Endothelial dysfunction of the coronary [Halcox et al.
2002b; Schachinger et al. 2000; Suwaidi et al. 2000] and peripheral arteries [Heitzer et
al. 2001; Neunteufl et al. 2000; Perticone et al. 2001b] is a marker of future
cardiovascular events and coronary revascularisation procedures in patients with CAD.
However, the association between non-invasively determined endothelial dysfunction, in
patients with underlying CAD, with cardiovascular and all-cause mortality or
revascularisation procedures is unknown.
Arterial stiffness and endothelial dysfunction are known to co-exist in a number of
disease states, such as diabetes [Wilkinson et al. 2000b], hypercholesterolaemia [Yacine
et al. 2000] and cardiovascular disease [Nigam et al. 2003], and appear to be determined
by common risk factors, for example obesity [Tounian et al. 2001], This study sought to
determine the relationship between non-invasive measures of arterial stiffness and
endothelial function.
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This chapter is aimed at assessing, in patients with CAD:
1. the determinants of endothelial function, particularly the influence of severity ofCAD
and cardiovascular risk factors, using the technique of non-invasive PWA.
2. the association between arterial stiffness and endothelial dysfunction.
3. the relationship between the presence of endothelial dysfunction with major adverse
cardiovascular events defined as cardiovascular and all-cause mortality, hospitalisation
due to cardiovascular causes (including non-fatal MI or stroke) and coronary




Subjects who participated in the study of arterial stiffness described in Chapter 5, were
recruited into this study. All studies were carried out in the Wellcome Trust Clinical
Research Facility at the Western General Hospital and at the Royal Infirmary,
Edinburgh.
6.2.2 Measurements
All subjects had their morning medications withheld following an overnight fast.
Brachial artery blood pressure was measured using an integrated automated
sphygmomanometer linked to an automated tonometric device containing piezo-electric
pressure sensors (Colin® CBM-7000, Colin Medical Technology Corporation, Japan)
coupled to a SphygmoCor® system (SphygmoCor® Mx Aortic Blood Pressure
Monitoring System, AtCor Medical, Australia). This automated tonometric device was
used to calculate the augmentation indices (AIx, AIx75, and PAIx) from centrally
derived and radial pressure waveforms.
The arterial stiffness measures - PWV, AIx, AIx75, PAIx, SI and RI — were assessed
by comparing them with endothelial function measures of peak values and area under
the curves (AUC) of the augmentation indices (AIx, AIx75 and PAIx) following the
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administration of GTN and salbutamol. Details of the methods used to measure arterial
stiffness are detailed in Chapters 2 and 5.
6.2.3 Study protocol
All subjects were rested for 10 minutes during which three baseline recordings were
made. Administration of GTN was recorded as time = 0 where 500 jUg of sublingual
GTN was administered under the tongue for a period of 3 minutes. Following this,
pressure wave recordings were taken every minute for 10 minutes and every 5 minutes
for the next 20 minutes. GTN has a short duration of action with haemodynamic changes
returning to baseline values within 20 minutes [Greig et al. 2005; Wilkinson et al.
2002b]. Therefore, in the present study salbutamol was administered 30 minutes after
the administration of GTN to allow the augmentation indices to return to baseline
values. A dose of 400 /xg of salbutamol was then administered over a period of 1 minute
via a Volumatic device at time = 33 minutes. Following this, measurements were taken
every minute for the next 10 minutes and every 5 minutes for the following 20 minutes.
In a previous study, the effect of salbutamol was shown to return to baseline within 30
minutes and therefore measurements of augmentation indices were recorded for a period
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6.2.4 Outcomes
Follow-up data obtained in 5.2.4 were used to determine whether endothelial
function is a predictor of fatal and non-fatal events.
6.2.5 Blood sampling and serum assays
Biochemical blood results obtained in Section 5.2.5 were used to analyse the
relationship between endothelial function and biochemical variables in both
univariate and multivariate analyses.
6.2.6 Data analysis
Statistical analysis was performed using Microsoft Excel 2002 and SPSS version
11.5 for Windows program (SPSS, Inc., Chicago, IL, USA). Box-plots of the overall
change in augmentation indices were computed using the R statistical programming
language 2003 (R Foundation for Statistical Computing, R Development Core Team,
Vienna, Austria) [R Development Core Team 2003]. There were no violations in the
assumptions of normality, linearity, and homogeneity of variances. Data are given as
mean ± SD. The first three baseline AIx measurements were averaged and this was
taken as the final baseline measurement. The final baseline measurement was
subtracted from subsequent measurements following GTN and salbutamol
administration. Thus, all values of augmentation indices for each subject were
normalised to their respective averaged baseline values. This procedure was repeated
for AIx75 and PAIx. These augmentation values were plotted as a function of time
from which the maximal negative change in the augmentation indices were
determined, denoted as the peak value, and to calculate the area under the curves
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(AUC) using the trapezoid rule. Peak values are defined as the largest negative
excursion (deviation) from baseline. Larger negative peak values imply larger
vasodilatation to the drugs.
The AUC gives a measure of the AUCs in augmentation indices as a function of
time, which is given by the following formula
AUCa.b = [AAIxta + AAIxtb] (tb-4)]/2
where AAIxta is the difference in AIx from baseline at time t=a, AAIxtb is the
difference in AIx from baseline at time t=b and AUCa-b is the AUC between the
segment at t=a and t=b.
The AUC for each drug was calculated as the sum of the individual segments for the
respective drugs. These are given by the following formulas
AUCgtn = £ AUC 0-33
AUCsa]butamol — ^ AUC 33-64
where AUCgtn is the area under the curve for the response to GTN between t = 0 and
t = 33 minutes and AUCsaibutamoi is the area under the curve for the response to
salbutamol between t = 33 and t — 64 minutes. In this study area under the curves
were observed to be negative with vasodilatation and positive due to
vasoconstriction.
The boxplot ofAIx over time for each subject was plotted by taking the average AIx
from times measurement at t = -lOmins, -5mins, and 0 minutes to give an overall
baseline average. This baseline average was deducted from each data measurement
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including each individual baseline measurement for that subject. Thus each time-
point is translated to bring all individual subject data curves to a common baseline.
This common baseline is labelled as AIx = 0. This was repeated for AIx75 and PAIx.
The boxes on the boxplots contain 50% of the data; the lines splitting each box are at
the positions of the medians or 50% quartiles; the lines representing the lower and
upper surfaces of the boxes are at the lower and upper quartiles, or the 25% and 75%
quartiles, respectively. The upper whiskers are at positions 1.5 times the interquartile
range higher than the upper quartile; and the lower whiskers are at positions 1.5
times the interquartile range lower than the lower quartile. The points represent data
outside these ranges.
Follow-up time was calculated as days between the first study visit and date of the
first cardiovascular event or date of last follow-up for censored subjects. The primary
pre-defined outcome of this study was a composite end-point consisting of death,
AMI, stroke and hospitalisation due to CHD while the post-hoc outcome studied was
future coronary intervention (CABG or PTCA). Cumulative survival and event-free
probabilities were determined using the Kaplan-Meier product-limit method and
compared by the Mantel (log-rank) test. Testing was two-sided and significance was
taken at the 5% level.
Univariate correlation coefficients were given as Pearson's r, and stepwise linear
regression was used for multivariate analysis. All parametric data were analysed
using Student's Mest, ANOVA and ANCOVA where appropriate. The Bonferroni
correction was used for post-hoc comparisons. All testing was two-sided and
significance was taken at the 5% level.
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6.3 RESULTS
Out of 288 subjects, 10 subjects had to be excluded due to difficulties in obtaining
good quality radial pressure pulse wave recordings. The remaining 278 subjects
formed the study population. The change in AIx with the administration ofGTN and
salbutamol is outlined in Figure 6-2. From the figure it is clear that the value ofAIx
changed after the administration of GTN and salbutamol. Following the
administration of GTN changes in AIx returned to baseline after 30 minutes.
Salbutamol, however, still had an effect 30 minutes after its administration. A similar
trend was found for AIx75 and PAIx. The peak changes in the augmentation indices
to GTN were bigger compared to those of salbutamol.
6.3.1 Demographic variables
Older subjects were found to have a smaller peak value and AUC of the
augmentation indices following the administration ofGTN. However, no relationship
was found between age and peak value or AUC of the augmentation indices
following salbutamol (Table 6.1). Subjects with a higher BMI had a smaller peak
value and AUC of the augmentation indices due to GTN and a smaller AUC in AIx
due to salbutamol. Sex was only found to contribute to a larger AUC in differences
in PAIx due to GTN in men compared to women (-178 ± 173 vs -129 ± 196; P <
0.05; independent f-test) while no association was found with smoking status.
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GTN Augmentation index 0.22f 0.14*
Augmentation index at HR 75 bpm 0.20** 0.14*
Peripheral augmentation index 0.18** 0.16**
Salbutamol Augmentation index 0.06 0.02
Augmentation index at HR 75 bpm 0.04 -0.02
Peripheral augmentation index 0.04 0.06
AUC
GTN Augmentation index 0.16** 0.17**
Augmentation index at HR 75 bpm 0.18** 0.14*
Peripheral augmentation index 0.12* 0.16**
Salbutamol Augmentation index -0.02 0.12*
Augmentation index at HR 75 bpm -0.02 0.10
Peripheral augmentation index -0.01 0.06
N=278 Values are Pearson's correlation coefficients (r) and are represented as means
± SD. * P < 0.05, **P < 0.01 f P < 0.001
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6.3.2 Biochemical variables
High serum creatinine concentrations and low GFR were associated with a smaller
peak change in AIx (r = 0.13, P < 0.05; r = -0.14, P < 0.05) and AIx75 (r = 0.13, P <
0.05; r = -0.14, P < 0.05) due to GTN. No association was found between serum
creatinine concentrations or GFR with changes in augmentation values due to
salbutamol. Surprisingly, higher serum triglyceride concentrations were associated
with a larger peak change in AIx75 to salbutamol (r = -0.13, P < 0.05) while the
Chol:HDL-C ratio was associated with a smaller AUC in AIx to GTN (r = 0.15, p =
0.05).
6.3.3 Determinants of vascular function
6.3.3.1 Endothelium-independent vasodilatation
Variables that were associated with endothelial function in univariate analysis were
further analysed in multivariate analysis and the results are shown in Table 6-2. The
R square value explains how much of the variance in the dependent variable is
explained by the model while the regression coefficients are used to construct the
regression equation for the model. From these results it is clear that age and BMI
were weak determinants of the peak value and AUC in AIx and AIx75 to GTN. Peak
changes in PAIx due to GTN were determined by age, heart rate and BMI, but only
BMI weakly determined AUC ofPAIx.
6.3.3.2 Endothelium-dependent vasodilatation
Peak values of AIx75 were weakly determined by ejection duration and serum
triglyceride concentration while the peak values of PAIx due to salbutamol were
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weakly determined by heart rate. The AUC of AIx for salbutamol was weakly
determined by central SBP while the AUC of AIx75 was determined by CSBP and
weight. The AUC of PAIx for salbutamol was not determined by any of the
variables.
6.3.4 Coronary artery disease
There were no differences in peak or AUC of the augmentation indices between
subjects with and without symptoms or presence ofCAD (Table 6-3) nor was there a












Number of diseased coronary vessels
Figure 6-3 Mean AUC of peripheral augmentation index against numbers of diseased
coronary vessels. Values are means ± SD.
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Table 6-2 Multiple regression analysis of endothelial function.






GTN AIx (R2=0.089, P < 0.001)
Age, years
BMI, kg/m2































PAIx (R2=0.029, P < 0.01)
HR, beats per minute 0.2 0.06|
AUC

















PAIx (R2=0.02, P < 0.01)
BMI 6.23 2.38**
Salbutamol AIx (R2=0.020, P < 0.05)
Central systolic blood pressure, mmHg -1.20 0.52*
AIx75 (R2=0.035, P < 0.01)






* P < 0.05, **P < 0.01, |P < 0.001
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There were no differences in peak values or AUC of the augmentation indices due to
GTN or salbutamol between subjects who were receiving and those who were not
receiving nitrates, calcium channel blockers (CCB) or ACE inhibitors after adjusting
for central mean blood pressure, total cholesterol and serum creatinine
concentrations. Patients on a /3-blocker had a larger peak change in PAIx to
salbutamol than those not on a /3-blocker (-13.7 ± 8.9 vs -11.6 ± 8.9; P < 0.05;
ANCOVA). Patients receiving nicorandil had a smaller AUC of PAIx due to GTN
and salbutamol compared to those not on nicorandil (-115 ± 178 vs -178 ± 179; P <
0.05; -60 ± 220 vs -140 ± 219; ANCOVA).
6.3.6 Endothelial function and smooth muscle dysfunction
The relationship between the endothelium-dependent and -independent changes in
augmentation indices was assessed to determine whether reduced endothelium-
dependent changes in augmentation indices were confounded by underlying
underlying smooth muscle dysfunction (Figure 6-4). Subjects who had small peak
values or AUC of AIx due to salbutamol also had small peak (r = 0.35, P < 0.000)
and AUC (r = 0.52, P < 0.000) of AIx due to GTN respectively. These trends were
also seen for AIx75 (r = 0.44 for peak changes; r = 0.36 for AUCs; P < 0.000) and
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6.3.7 Outcomes
Follow-up data was obtained from Section 5.3.8.
6.3.7.1 Endothelium-independent and -dependent changes in augmentation indices
as predictors of outcomes
A smaller peak change in PAIx due to GTN was found in subjects who suffered an
event compared to subjects who did not suffer an event (-18.5 ± 7.6 vs —21.1 ± 9.4
%; P < 0.05; /-test). When subjects were divided into quintiles of peak or AUCs in
the augmentation indices due to GTN, there were no differences between the groups.
There were also no differences in the quintiles of peak and AUC of the augmentation
indices following salbutamol.
6.3.8 Arterial stiffness and endothelial function
Arterial stiffness and endothelial function were analysed in 278 subjects. PWV
measures were only available in 238 subjects of the 278 subjects. Subjects with high
PWVs had smaller peak response to GTN as well as a smaller AUC in augmentation
indices. There were, however, no correlations between PWV and measures of
augmentation indices following salbutamol (Table 6-4).
Baseline AIx, AIx75 and PAIx negatively correlated with peak changes in
augmentation indices following GTN and salbutamol. That is to say, subjects with
the higher stiffness as measured by AIx, AIx75 and PAIx had a higher peak response
to GTN and salbutamol. Higher AIx, AIx75 and PAIx values were also correlated
with a larger AUC in augmentation indices following GTN and salbutamol.
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However, arterial stiffness as measured by SI and RI, showed no correlation with
measures of endothelial function.
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Both GTN and salbutamol reduced the augmentation indices as a function of time with
GTN having a shorter duration of action but a greater peak effect compared to
salbutamol. Both the endothelium-dependent and independent changes in augmentation
indices were weakly explained by blood pressure and BMI but not by the presence or
severity of CAD, renal function or serum cholesterol and lipid concentrations.
Moreover, they did not predict fatal and non-fatal cardiovascular outcomes. Our
findings suggest that non-invasive assessment of endothelial function using measures of
arterial stiffness do not correlate with established markers of cardiovascular risk nor
predict outcome in patients with CAD.
The age-associated impairment in endothelium-independent vasodilatation may reflect
underlying impairment of relaxation of smooth muscle cells. However, there was a lack
of association between endothelium-dependent changes in augmentation indices and
age. This is in contrast to large studies [Celermajer et al. 1994a; Herrington et al. 2001]
that have shown an inverse relationship between endothelial function and age. This
difference may be explained by the fact that these former studies have mainly been
carried out in healthy subjects [Celermajer et al. 1994b] or have not assessed
endothelium-independent vasodilator response [Herrington et al. 2001], Age explains
only a small percentage of the variance in endothelium-dependent vasodilatation
[Benjamin et al. 2004] and we cannot exclude a small effect. Other factors than age may
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have had a larger role in the development of endothelial dysfunction. The peak
augmentation indices and AUC for GTN were similarly associated with age and BMI.
Therefore, either the peak value or AUC may similarly reflect the extent of endothelium-
independent vasodilatation. However, the different associations between salbutamol-
mediated peak augmentation values and AUC with age or BMI may have resulted from
incomplete capture of measurements and hence an underestimation of the AUC for the
salbutamol response which persisted 30 minutes following salbutamol administration.
A low BMI was also associated with larger endothelium-independent peak and AUCs of
the augmentation indices but not endothelium-dependent peak and AUCs. This is
consistent with previous findings of no association between changes in AIx due to
salbutamol and weight or BMI, using the technique of peripheral waveform analysis
[Hayward et al. 2002]. Subjects in the present study were not given weight adjusted
doses of salbutamol which may have resulted in varying volume of distributions
(normally 7.2 - 9 L/Kg) of the drug. Moreover, BMI values are confounded by muscle
mass. Therefore visceral fat distribution, a measure of adiposity, may be a more useful
determinant of endothelium-dependent changes in augmentation indices as shown in a
study of obese premenopausal women [Suh et al. 2005], Abdominal fat distribution has
been shown to be correlated with other measures of endothelial functon [Perticone et al.
2001a; Tounian et al. 2001].
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6.4.1 Biochemical parameters
Hypercholesterolaemia increases the risk of CAD [Castelli 1984] and is associated with
impaired endothelial function [Cardillo et al. 2000; Casino et al. 1995; Lewis et al.
1999], even in angiographically normal coronary arteries [Quyyumi et al. 1997]. Unlike
previous findings of an association between endothelial dysfunction and
hypercholesterolaemia, the lack of relationship between serum cholesterol and lipid
concentrations with endothelial function in this study may be a reflection of the large
numbers of subjects on cholesterol lowering therapy. This may have resulted in well
controlled cholesterol and lipid concentrations which obscured the relationship with
measures of endothelium-dependent and independent changes in augmentation indices.
Moreover, total serum triglyceride concentrations may not represent the atherogenic
triglyceride-containing lipoproteins such as VLDL or chylomicron remnants [Jeppesen
et al. 1998].
Patients with chronic renal failure [Thambyrajah et al. 2000] or hypertension who have
reduced renal function [Perticone et al. 2004] have been shown to have impaired
endothelium-dependent dilatation. In the present study, subjects with a lower renal
function values had lower endothelium-independent changes in augmentation indices but
no association was found with endothelium-dependent changes in augmentation indices.
The relationship between endothelium-independent changes in augmentation indices and
renal function, however, was weak and did not persist in multivariate analysis.
Therefore, in the present cohort of subjects with CAD, other factors may play a larger
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role in the development of systemic endothelial dysfunction, rather than impaired renal
function, such as increased oxidative stress.
6.4.2 Blood pressure and cardiovascular risk
A number of earlier studies [Gokce et al. 2001; Panza et al. 1993] have shown an
association between endothelial dysfunction and hypertension. In the present study,
central SBP was found to be a small determinant (2%) of endothelium-dependent
changes in augmentation indices and, in contrast, a higher SBP was associated with a
larger AUC for salbutamol. However, this was a weak association which did not persist
on assessment of peripheral SBP. This association may be a result of an underestimation
of the AUC for salbutamol.
The lack of relationship between the presence or absence of CAD and endothelial
dysfunction may be due to subjects with angiographically normal coronary arteries
having underlying coronary microvascular dysfunction [Quyyumi et al. 1992], or
segments of coronary arteries which are functionally abnormal [Tentolouris et al. 2000]
(as for example, in patients with syndrome X) which is not detectable by angiography.
Moreover, impaired endothelial function resulting from early atherosclerosis has been
previously shown to be present in each of the following groups of patients: those with
normal coronary arteries, those presenting with chest pain, and those presenting with
risk factors for atherosclerosis [Tentolouris et al. 2000; Tousoulis et al. 1996].
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When assessing symptoms and severity of CAD, no association was found with the
presence of endothelial dysfunction nor was there a difference between subjects with
and without CAD. There are four possible reasons why we did not find an association.
First, these patients had multiple risk factors such as hypertension, diabetes and
hypercholesterolaemia. Therefore, it is not known to what extent these risk factors
contributed to endothelial dysfunction and the cumulative effect of these risk factors on
the endothelium. Second, coronary angiography does not accurately quantify the burden
of atherosclerosis of the coronary or systemic arteries. The severity of endothelial
dysfunction of the systemic arteries may not parallel the severity of endothelial
dysfunction of the coronary arteries. Third, the majority of subjects were on long-term
multiple drug therapies which may have influenced endothelial function. Fourth,
technical problems with the technique may have undermined the association between
endothelial dysfunction and CAD severity. The period between the administration of
GTN and that of salbutamol may not have completely precluded any persistent effect of
GTN in some subjects. The peak effect may have been missed due to insufficient
measurements after the first 11 minutes following salbutamol administration. In
addition, changes in augmentation indices following salbutamol persisted following a
period of 30 minutes and therefore the complete response to salbutamol is not known.
Our findings would suggest that the technique used in this study, is not a good test of
endothelial function in patients with CAD.
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Drug therapy was assessed to determine its effects on endothelial function measures but
is inconclusive. Subjects in the present study were on multiple drug therapy making it
difficult to determine whether any one particular drug is associated with better
endothelial function measures.
6.4.3 Endothelium-dependent and -independent response
GTN is denitrated in smooth muscle cells causing NO to be released and resulting in
vasodilatation [Abou-Mohamed et al. 2000], In contrast, the vasodilatory effect of
salbutamol is only partly mediated by NO [Dawes et al. 1997; Wilkinson et al. 2002b].
Therefore, salbutamol-mediated vasodilatation may be additionally caused by other
mechanisms such as endothelium-dependent hyperpolarising factor which acts through
calcium-activated potassium channels on smooth muscle cells resulting in smooth
muscle cell hyperpolarisation and relaxation [Bellien et al. 2005]. NO-independent
vasodilatation may also be caused by prostanoids such as prostacyclin increasing cAMP
[Lamping 2001]. This implies that the changes in the augmentation indices to salbutamol
may not be a specific measure of the severity of impaired NO-mediated vasodilatation of
smooth muscle cells.
The changes in augmentation indices to salbutamol may be explained by polymorphisms
of the human B2 adrenoreceptor responsible for interindividual variation in expression,
regulation and function of the B2 adrenoceptor [Green et al. 1994; Johnson 2006;
Reihsaus et al. 1993], A coding region on the 62 adrenoceptor gene can have several
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genetic polymorphisms [Cho et al. 2005; Joos et al. 2002], The effect of these
polymorphisms on the reduction in AIx to inhaled salbutamol is currently not known.
Therefore, there is a potential that this polymorphism may result in a degree of
variability in augmentation measures which is not determined by endothelial function.
In the present study, both the endothelium-dependent and independent changes in
augmentation indices are strongly and positively correlated. Patients with CAD have
previously been shown to have a reduced response to endothelium derived [Adams et al.
1998] as well as exogenous nitrovasodilators [Raitakari et al. 2001]. A number of
studies also suggest that the endothelium-independent response is an important predictor
of adverse cardiovascular events. A lower vasodilatory response to GTN has been shown
to predict adverse cardiovascular events, in patients with CAD [Schachinger et al. 2000],
while a study of patients with chest pain [Neunteufl et al. 2000] found a larger GTN-
mediated vasodilatory response to be associated with an increase in myocardial
infarction and to predict adverse cardiovascular events. The results of the latter study
may be a result of hypersensitivity of the artery to GTN due to deficient endothelial NO
activity or patients at high risks ofMI having an increased vasoconstrictor response to
endogenous vasoconstrictors. However, both these studies highlight the importance of
the endothelium-independent response as predictors of cardiovascular outcomes. In the
present study, however, it is difficult to distinguish whether the endothelium-dependent
changes in augmentation indices were due to the presence of endothelial dysfunction,
smooth muscle dysfunction or a combination of both.
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6.4.4 Arterial stiffness and endothelium-independent and -dependent changes
in augmentation indices
In this study, arterial stiffness was unrelated to endothelial function but associated with
endothelium-independent changes in augmentation indices. One explanation of this
finding is that the artery may be very stiff and therefore it restricts the endothelium-
dependent and independent vasodilatory response. In addition, salbutamol may be a less
potent vasodilator and therefore the endothelium-dependent vasodilatory response may
have only been partially stimulated.
6.4.5 Endothelium-independent and -dependent changes in augmentation
indices as predictors of outcomes
The severity of coronary atherosclerosis is associated with the severity of coronary
endothelial dysfunction in patients with angiographically normal coronary arteries,
assessed by intravascular ultrasonography [Matsuda et al. 2003] and in patients with
atherosclerotic coronary arteries [Matsubara et al. 2003], and predicts cardiovascular
outcome [Halcox et al. 2002a; Suwaidi et al. 2000; Vita et al. 1990]. Although the
coronary circulation is of most relevance, peripheral endothelial dysfunction has also
been shown to be associated with coronary endothelial function [Anderson et al. 1995b;
Takase et al. 2005] and CAD severity [Thanyasiri et al. 2005; Wu et al. 2005]. In
addition, peripheral endothelial function predicts cardiovascular outcome [Gokce et al.
2002; Heitzer et al. 2001; Kuvin et al. 2001; Neunteufl et al. 2000].
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The endothelium has important antiatherogenic effects which are mediated by NO such
as inhibition of smooth muscle proliferation, platelet aggregation, oxidation of LDL-C,
adhesion of leukocytes and it counteracts vasoconstrictor forces. The studies above
allude towards an association between the severity of endothelial dysfunction in the
peripheral and coronary circulation and with coronary atherosclerosis. However, in the
current study, endothelial dysfunction was neither associated with CAD severity (as
detailed in Chapter 6) nor was it associated with cardiovascular outcomes. This
difference may be due to coronary structure being more predictive of outcome rather
than functional measurements (endothelial function) [Asselbergs et al. 2004;
Schachinger et al. 2000]. Atherosclerosis is also known to less commonly develop in the
forearm as compared to the coronary arteries [Anderson et al. 1995b] and therefore
atherosclerosis in the forearm and the coronary circulation may not be linearly
associated.
6.4.6 Study limitations
There are a number of limitations of this study: first, subjects classified as not having
CAD were not a true healthy population and therefore were not an ideal comparator
group. Second, the majority of subjects were on long-term drug therapies which may
have modified endothelial function and resulted in the lack of association with the
presence or severity of CAD. Third, this study was not designed to assess mechanisms
that underlie the reduced change in the augmentation indices to GTN or salbutamol.
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Fourth, subjects were on long-term nitrates and/or /3-blockers which may have
underestimated the vasodilatory effects to GTN and salbutamol respectively. Long-term
nitrate therapy can lead to the development of nitrate tolerance causing a lower
vasodilatory response to GTN and an underestimation of the endothelium-independent
peak and AUC values. Fifth, there are limitations with the technique. The vasodilatory
action of salbutamol is only partly mediated by NO, and therefore there may be
vasodilatation in the presence of a dysfunctional endothelium. In addition, there may be
some persistent residual dilatation due to GTN during the administration of salbutamol
which may have led to an overestimation of the vasodilatory response. Sixth, it is
difficult to determine to what extent endothelial function measurements have been
confounded by smooth muscle dysfunction or loss of smooth muscle sensitivity to NO.
This may have affected the associations between arterial stiffness and endothelial
function. Finally, the small numbers of fatal events were small and therefore limited the




The technique of pressure PWA in combination with the administration of GTN and
salbutamol is not a good test of endothelial function in patients with CAD and therefore
its association with standard cardiovascular risk factors and renal function cannot be
determined. Moreover, endothelial function measured using this technique does not
provide any valuable information on fatal and non-fatal outcomes.
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CHAPTER 7: CONCLUSIONS AND FUTURE WORK
7.1 SUMMARY
In this thesis, I describe how I assessed the reproducibility of skin elasticity
measurements and endothelial function in healthy subjects and subjects with CAD
respectively. Having established both techniques as being reproducible, I went on to
assess skin elasticity as an alternative marker of arterial elasticity in a healthy group of
subjects. Skin elasticity was not a reliable marker of arterial elasticity, and therefore I
went on to assess arterial stiffness using conventional and a newer non-invasive
methodology (DVP analysis) in patients with CAD. I also incorporated the newer non¬
invasive technique of pressure PWA with salbutamol, as a test of endothelial function, in
this cohort of subjects. Endothelial function was measured using an automated tonomtric
device, Colin® 7000, coupled to a SphygmoCor® system which was found to be in good
agreement with a more commonly used device, the Millar micromanometer. Next, the
relationship between arterial stiffness and endothelial function with the presence and
severity of CAD, and cardiovascular risk factors was assessed. Finally, I examined the
relationship between arterial stiffness and endothelial function in subjects with CAD and
the survival of subjects from cardiovascular morbidity and all-cause mortality as





Before studying the relationship between skin and arterial elasticity, it was necessary to
assess the reproducibility of skin measurements in order to ensure that this methodology
would produce valid consistent measurements in a clinical setting. It was also necessary
to determine the region of the skin which may be least affected by external factors and
the most closely associated with changes in the arteries. Skin elasticity measurements
were carried out in the leg, arm and back and involved the R2, R5, R6 and R7 skin
elasticity ratios. This study showed skin elasticity measurements were most reproducible
in the upper leg and upper arm and the most reproducible skin elasticity ratio was the R6
ratio.
Whilst the above results showed good reproducibility, reproducibility of skin elasticity
measurements may be improved by pre-tensioning [Serup et al. 1995] the skin by
applying suction for a short period of time on the surface of the skin before
measurements of vertical deformation. This pre-conditioning reduces the contribution of
lateral displacement to the vertical displacement measurements.
In any future studies the absolute skin elasticity parameters, which have been adjusted
for dermal skin thickness, should be studied where possible as they are measures of
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individual absolute parameters rather than ratios of absolute parameters (relative
parameters) [Dobrev 2002]. The individual absolute parameters would give more
information on the contribution of specific components such as the elastic and viscous
components. Skin thickness can be measured using the method of ultrasonic echography
as described by Alexander and Miller [Alexander et al. 1979; Escoffier et al. 1989],
however, it is currently not a clinically useful method.
7.2.1.2 Endothelial Function
The non-invasive assessment of endothelial function using the technique of PWA has
previously been carried out in a small number of patients with hypercholesterolaemia
[Wilkinson et al. 2002b] and CAD [Hayward et al. 2002], In this thesis I aimed to
investigate the reproducibility of the PWA technique in subjects with CAD, whereby
GTN was administered first followed by the administration of salbutamol 30 minutes
later, as a potential tool for clinical risk assessment. This study showed that the changes
in augmentation indices due to salbutamol were reproducible. However, the
reproducibility of this technique may have been improved by a longer training period,
prior to undertaking the study, of inhaling salbutamol via a Volumatic device.
7.2.2 Skin elasticity as a marker of arterial elasticity
Skin and arterial elasticity were weakly associated, with age being the largest
determinant of arterial elasticity. However, the differences in the mechanistic effect of
skin and arterial elasticity measures, could not be addressed, as there is no means of
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determining the stress-strain curves of elastin and collagen in the aorta to be compared
with that of the skin. We, however, do not know if skin elasticity and arterial elasticity
are more closely associated in patients with vascular diseases, in whom other factors
may be a more important determinant than age.
7.2.3 Determinants of arterial stiffness in CAD patients
PWV was a more useful correlate of arterial stiffness than the augmentation, stiffness
and reflection indices. Renal function, rather than standard cardiovascular risk factors,
was associated with the stiffness of arteries in this cohort of subjects who had underlying
CAD. Importantly, renal function, within the normal range, remained an independent
predictor of arterial stiffness. This study, however, did not assess the underlying
mechanism of the association between arterial stiffness and renal function, and therefore
it is not known whether reduced renal function is a cause or effect of arterial stiffness in
this group of subjects. When subjects were followed up for a period of 18 months, the
presence of CAD, severity of CAD, stiffness of arteries and eGFR were predictive of
cardiovascular events including death. Subjects who participated in this study were
stable and are, therefore, more likely to have a low number of events. Therefore,
extending the follow-up of subjects to 5 years is more appropriate, to investigate the key
determinants of long term cardiovascular outcomes in this cohort of subjects.
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7.2.4 Determinants of endothelial function in CAD patients
Subjects with CAD had a smaller change in augmentation indices to salbutamol
compared to GTN. However, the salbutamol mediated changes in AIs were not
dependent on standard cardiovascular risk factors or renal function. Moreover,
endothelial dysfunction was not predictive of fatal and non-fatal outcomes. Changes in
the augmentation indices following GTN were associated with changes in augmentation
indices following salbutamol. However, we do not know whether this association is
mediated by the presence of endothelial dysfunction and/or the presence of smooth
muscle dysfunction. In addition, the association between arterial stiffness and changes in
augmentation indices due to GTN but not salbutamol may also be affected by smooth
muscle dysfunction.
The time required for endothelium-dependent changes in augmentation indices to return
to baseline will need to be evaluated by carrying out a time response curve. This will
lead to more accurate measurements of the AUC of the augmentation indices following
salbutamol administration in future studies. Furthermore, one approach that may be
useful, in future studies, would be to investigate the ratio of changes in augmentation
indices of salbutamol following GTN, which reflects normal endothelial function, and
the relationship of this ratio with the severity of vascular diseases such as
hypercholesterolaemia, diabetes or renal disease.
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7.3 CONCLUSIONS
Skin elasticity is not a marker of arterial elasticity and the very weak association does
not justify further investigation, particularly in healthy volunteers. In treated patients
with CAD, PWV is not determined by the severity of CAD or traditional CV risk
factors. However, renal function is an important contributor to the variance in PWV. The
severity ofCAD, PWV and renal function are important predictors of fatal and non-fatal
cardiovascular events.
The administration of salbutamol in combination with pressure wave analysis is not a
useful test of endothelial function and does not provide any prognostic information that
will be useful in the clinical management of patients with CAD on pre-existing
treatments. Moreover, endothelial function is not associated with arterial stiffness in this
treated population. However, in order to justify the lack of prognostic information and
association with arterial stiffness, endothelial function should be assessed prior to
starting treatment in CAD patients. The endothelial function protocol should also be
revised to carry out measurements of the endothelium-dependent and -independent
changes in augmentation indices on separate occasions to avoid any overlapping
influence of either drug. In addition, more measurements should be taken to identify the
peak effect and a longer time frame of the salbutamol-mediated response should be
assessed in order to gather complete AUCs.
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7.4 FUTURE DIRECTIONS
In order to better understand if there is a pathological relationship between skin elasticity
and arterial stiffness it is proposed that skin and arterial elasticity be assessed in diabetic
patients who are predisposed to accelerated stiffening of arterial connective tissue.
Patients with diabetes would be an ideal study population as intrinsic (pathological or
genetically mediated factors), rather than extrinsic factors (external factors such as
ultraviolet light, temperature and humidity), would play a larger role. They may also
present with changes in connective tissue at an earlier age [Braverman et al. 1984] and
therefore more remarkable changes in skin elasticity and arterial stiffness may be seen
within a narrower age range. In addition, there are a large number of alternative
techniques (e.g. high-frequency B-mode ultrasound) available to measure skin elasticity
that are promising [de Rigal et al. 1989; Serup et al. 1995]. To date, however, there is a
lack of standardisation of their application for measuring biophysical properties of the
skin.
A suggestion for further research is to investigate the underlying relationship between
deteriorating renal function and stiffening of the large elastic arteries in patients with
CAD who have not been started on drug treatment. This will eliminate any confounding
effect that drugs may have on arterial structure and function, and on renal function.
Large longitudinal studies are required to determine the relationship and progression of
arterial stiffness with renal function in patients with CAD. Moreover, large
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interventional studies are needed to delineate which drug classes most influence arterial
stiffness and renal function. For example, by aggressivly lowering blood pressure in
patients with CAD, we could evaluate the role of blood pressure in impairment of renal
function through its damaging effect on the glomeruli. Another study for the future
would be to evaluate the effect of antioxidants, such as vitamins C and E [Sies 1997], on
vascular and renal function. Oxidative stress is known to be associated with
atherosclerotic disease in patients with diabetes, renal disease and hypercholesterolaemia
[Heistad 2006]. Importantly, oxidative stress results in an impairment of renal function
via a reduction in glomerular filtration capacity and/or an increase in renal
vasoconstriction and it is a marker of cardiovascular events [Himmelfarb 2005; Locatelli
et al. 2003]. Therefore, it would be important to evaluate the effect of antioxidants on
the progression or improvement of arterial stiffness and renal dysfunction. In addition,
analysis of markers of reactive advanced glycation end-product (AGE) formation
(urinary pentosidine and pyrraline), a measure of carbohydrate oxidation, may explain
the high stiffness in patients with CAD who have low eGFRs [Falcone et al. 2005;
Hudson et al. 2005; Kalousova et al. 2006], AGEs are formed through the non-
enzymatic reaction between glucose and reducing sugars with protein amino groups
which results in the formation of stable Amadori products [Bucala et al. 1995;
Tsukahara et al. 2003]. A small proportion of this product is transformed into AGEs
irreversibly. AGEs are found in collagenous structures, such as basement membranes
and vascular wall collagen and lead to collagen cross-linking. Moreover, AGEs increase
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endothelial permeability and bind to AGE-specific receptors, for example on endothelial
cells, vascular smooth muscle cells, and glomerular mesangial cells resulting in
increased inflammation, oxidative stress, oxidation of LDL and a reduction in the
vasodilator and antiproliferative effects ofNO.
An important factor in future studies is the analysis of asymmetrical dimethylarginine
(ADMA), an endogenous inhibitor of NO synthase [Vallance et al. 2004], ADMA is
partially excreted by the kidneys and, therefore, the plasma concentration of ADMA is
increased in patients with renal failure [Fliser et al. 2005; Vallance et al. 1992],
Moreover, plasma ADMA concentrations predict all-cause mortality and cardiovascular
outcomes in patients on haemodialysis and in ESRD [Valkonen et al. 2001; Zoccali et
al. 2001]. Therefore, by measuring plasma ADMA concentrations in future studies we
will be able to assess its role as a risk factor in patients with CAD and it's role as an
important prognostic indicator in patients with CAD.
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